Data / Research funding / Ovarian Cancer
Ovarian Cancer: 565 NIH awards ($586.3M) to 187 organizations
565 NIH awards ($586.3M) in the NIH spending category Ovarian Cancer, to 187 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
The 500 largest of 565 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| West Virginia IDeA Network of Biomedical Research Excellence (WV-INBRE) | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $20,261,619 | September 30, 2001 | July 31, 2029 | JOSHI, TRUPTI | reporter.nih.gov |
| Life Course Cancer Epidemiology Cohort in Women | NIH | National Cancer Institute | 2021 to 2025 | $15,280,631 | June 1, 2013 | August 31, 2028 | ELIASSEN, A. HEATHER | reporter.nih.gov |
| Kansas Center for Metabolism and Obesity REsearch (KC-MORE) | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $10,233,525 | April 1, 2022 | February 28, 2027 | WEINMAN, STEVEN A | reporter.nih.gov |
| Identifying Multilevel Drivers of Differences in Ovarian Cancer Treatment and Survival: An Integrative Approach | NIH | National Cancer Institute | 2021 to 2025 | $5,668,317 | July 1, 2020 | June 30, 2027 | DOHERTY, JENNIFER ANNE | reporter.nih.gov |
| Homology-directed repair: BRCA2 and RAD51 paralogs | NIH | National Cancer Institute | 2021 to 2025 | $5,007,139 | August 1, 2020 | July 31, 2027 | JASIN, MARIA | reporter.nih.gov |
| Trial of Exercise and Lifestyle (TEAL) in Women with Ovarian Cancer | NIH | National Cancer Institute | 2022 to 2025 | $4,851,495 | May 23, 2022 | April 30, 2027 | IRWIN, MELINDA L | reporter.nih.gov |
| Ovarian Cancer Survival in African-American Women | NIH | National Cancer Institute | 2021 to 2024 | $4,527,423 | July 1, 2020 | June 30, 2026 | SCHILDKRAUT, JOELLEN M. | reporter.nih.gov |
| Relating Molecular Subgroups of Endometriosis-Associated Ovarian Cancers to Survival and Risk | NIH | National Cancer Institute | 2021 to 2025 | $4,355,861 | January 13, 2021 | December 31, 2026 | GOODE, ELLEN L. | reporter.nih.gov |
| Metabolic reprogramming of the tumor microenvironment and therapy resistance | NIH | National Cancer Institute | 2021 to 2025 | $4,171,362 | August 17, 2021 | July 31, 2028 | LENGYEL, ERNST | reporter.nih.gov |
| Stalled replication fork repair in cancer predisposition and cancertherapy | NIH | National Cancer Institute | 2022 to 2025 | $4,040,847 | August 10, 2022 | July 31, 2029 | SCULLY, RALPH | reporter.nih.gov |
| MD Anderson Cancer Center EDRN- Clinical Validation Center for Early Detection of Ovarian Cancer with a multiple marker algorithm | NIH | National Cancer Institute | 2021 to 2025 | $3,471,925 | May 5, 2016 | May 31, 2028 | BAST, ROBERT C | reporter.nih.gov |
| New Approaches to Modeling and Targeting Cyclin E-amplified High-Grade Serous Tubo-Ovarian Carcinoma | NIH | National Cancer Institute | 2021 to 2025 | $3,453,304 | December 10, 2020 | November 30, 2025 | NEEL, BENJAMIN G. | reporter.nih.gov |
| Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system | NIH | National Cancer Institute | 2021 to 2025 | $3,433,365 | July 1, 2021 | June 30, 2027 | BOTA, DANIELA ANNENELIE | reporter.nih.gov |
| Extracellular Vesicle Proteomic Fingerprinting of Ovarian Cancer for Early Detection with a Nanoengineered Microsystem | NIH | National Cancer Institute | 2021 to 2025 | $3,402,215 | April 1, 2021 | March 31, 2026 | GODWIN, ANDREW K. | reporter.nih.gov |
| Career Development in Pediatric and Medical Oncology | NIH | National Cancer Institute | 2021 to 2025 | $3,314,336 | September 30, 1997 | August 31, 2026 | MESHINCHI, SOHEIL | reporter.nih.gov |
| Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer | NIH | National Cancer Institute | 2022 to 2025 | $3,252,105 | April 1, 2022 | August 31, 2027 | POWELL, DANIEL J. | reporter.nih.gov |
| Addressing Chemoresistance in Pancreatic and Ovarian Cancers: Photodynamic Priming and Repurposing of Tetracyclines using Targeted Photo-Activable Multi-Inhibitor Liposome | NIH | National Cancer Institute | 2021 to 2025 | $3,218,280 | April 1, 2021 | March 31, 2027 | HUANG, HUANG CHIAO | reporter.nih.gov |
| Ovarian Cancer Detection with Blood- and Imaging-Based Biomarkers | NIH | National Cancer Institute | 2022 to 2025 | $3,193,113 | January 1, 2022 | December 31, 2026 | BARTON, JENNIFER KEHLET | reporter.nih.gov |
| A Patient-Centric Approach to Advance Functional Precision Oncology | NIH | National Cancer Institute | 2023 to 2025 | $3,167,628 | September 22, 2023 | August 31, 2028 | KEMP, CHRISTOPHER J | reporter.nih.gov |
| Spatial functional genomics to identify regulators of the tumor microenvironment and cancer immunity | NIH | National Cancer Institute | 2023 to 2025 | $3,154,814 | September 19, 2023 | August 31, 2028 | BROWN, BRIAN D | reporter.nih.gov |
| Mechanisms of Genome Integrity | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,001,194 | May 1, 2016 | April 30, 2027 | GREENE, ERIC C | reporter.nih.gov |
| Synthetic and translational studies of antitumor and antimicrobial natural products. | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,988,144 | May 1, 2019 | April 30, 2029 | HERZON, SETH B. | reporter.nih.gov |
| Development of Novel Ovarian Cancer Biomarkers for Early Detection Algorithms | NIH | National Cancer Institute | 2021 to 2024 | $2,974,491 | September 1, 2020 | May 31, 2026 | LOKSHIN, ANNA E. | reporter.nih.gov |
| DIRAS3 disrupts K-RAS clustering and signaling, enhancing autophagy and response to autophagy inhibition | NIH | National Cancer Institute | 2022 to 2025 | $2,923,293 | September 21, 2022 | August 31, 2027 | BAST, ROBERT C | reporter.nih.gov |
| Breast Cancer PARP PET Imaging AIP to Support FDA Approval & Commercialization | NIH | National Cancer Institute | 2021 to 2025 | $2,907,069 | March 24, 2021 | February 28, 2026 | MANKOFF, DAVID A. | reporter.nih.gov |
| Dual-targeted DOTA CAR T cells with image-guided monitoring for solid tumor treatment | NIH | National Cancer Institute | 2024 to 2025 | $2,906,182 | September 9, 2024 | August 31, 2026 | POWELL, DANIEL J. | reporter.nih.gov |
| A Role of Multilevel Healthcare Access Dimensions in Ovarian Cancer Disparities | NIH | National Cancer Institute | 2021 to 2025 | $2,896,616 | August 1, 2024 | May 31, 2026 | AKINYEMIJU, TOMI F | reporter.nih.gov |
| Understanding the role of TP53 mutation in genetic susceptibility to ovarian cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,848,600 | April 1, 2021 | March 31, 2027 | RISQUES, ROSA ANA | reporter.nih.gov |
| Dynamic Interactions of the Ovarian-Fallopian Axis in High Grade Serous Ovarian Cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,809,429 | July 10, 2019 | June 30, 2029 | BURDETTE, JOANNA E | reporter.nih.gov |
| A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T cells Targeting TAG72 in Patients with Recurrent Epithelial Ovarian Cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,785,861 | September 1, 2022 | June 30, 2027 | RODRIGUEZ-RODRIGUEZ, LORNA | reporter.nih.gov |
| Targeting CDK7 in CCNE1-amplified Ovarian Cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,774,294 | February 17, 2022 | January 31, 2027 | GRAY, NATHANAEL SCHIANDER | reporter.nih.gov |
| Defining the role of BARD1 in nucleosomal ubiquitylation | NIH | National Cancer Institute | 2021 to 2025 | $2,722,483 | April 1, 2021 | March 31, 2027 | KLEVIT, RACHEL E | reporter.nih.gov |
| Expanding early cancer detection with high throughput OCEANA - Ovarian Cancer Exosome Analysis with Nanoplasmonic Array | NIH | National Cancer Institute | 2023 to 2025 | $2,713,023 | September 19, 2023 | August 31, 2028 | LEE, HAKHO | reporter.nih.gov |
| Metabolic and epigenetic reprogramming in cyclin E high ovarian cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,643,154 | May 1, 2021 | September 1, 2025 | AIRD, KATHERINE MARIE | reporter.nih.gov |
| Impact of aging on metastatic competence of the omentum | NIH | National Cancer Institute | 2025 | $2,638,738 | August 1, 2025 | July 31, 2029 | NAORA, HONAMI | reporter.nih.gov |
| Novel targeted therapy for treating Ovarian Cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,633,406 | August 1, 2022 | July 31, 2027 | VADLAMUDI, RATNA K | reporter.nih.gov |
| Mechanistic maps of adaptive responses to therapeutic stress to optimize combination therapies. | NIH | National Cancer Institute | 2021 to 2025 | $2,603,119 | April 1, 2021 | March 31, 2026 | MILLS, GORDON B. | reporter.nih.gov |
| Targeting complement to enhance antitumor immunity and control malignant effusions in patients with recurrent epithelial ovarian cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,601,255 | August 24, 2022 | July 31, 2027 | ZSIROS, EMESE | reporter.nih.gov |
| Development and Implementation of ElectronicDecision Aids for Genetic Testing in Inherited Cancer Syndromes | NIH | National Cancer Institute | 2021 to 2024 | $2,589,338 | September 14, 2020 | August 31, 2025 | CHUNG, DANIEL C | reporter.nih.gov |
| Integrating Epigenetic Modulation into DNA Damage Repair | NIH | National Cancer Institute | 2022 to 2025 | $2,584,072 | June 6, 2022 | May 31, 2027 | MUNSTER, PAMELA N. | reporter.nih.gov |
| Subcellular enzyme-instructed self-assembly for molecular anticancer nanomedicines | NIH | National Cancer Institute | 2021 to 2025 | $2,533,780 | February 8, 2010 | August 31, 2026 | XU, BING | reporter.nih.gov |
| Systems analysis of mechanisms driving response to immunotherapy in clear cell cancers | NIH | National Cancer Institute | 2022 to 2025 | $2,526,750 | September 13, 2022 | August 31, 2027 | GENTLES, ANDREW J. | reporter.nih.gov |
| Targeting B7-H3 in ovarian cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,515,188 | February 1, 2021 | January 31, 2027 | DOTTI, GIANPIETRO | reporter.nih.gov |
| Changing Contraceptive Patterns and Ovarian Cancer Risk | NIH | National Cancer Institute | 2021 to 2025 | $2,492,482 | April 1, 2021 | March 31, 2027 | TERRY, KATHRYN L. | reporter.nih.gov |
| Developing macrophage reprogramming mRNA nanocarriers for initial clinical testing | NIH | National Cancer Institute | 2021 to 2024 | $2,491,070 | April 1, 2022 | July 31, 2025 | STEPHAN, MATTHIAS | reporter.nih.gov |
| A paradigm shift for ovarian cancer biomarkers: Utilizing routine Pap tests as liquid biopsies for the development of targeted mass spectrometry-based proteomic assays for early detection | NIH | National Cancer Institute | 2021 to 2025 | $2,485,991 | August 5, 2021 | July 31, 2026 | SKUBITZ, AMY PATRICE | reporter.nih.gov |
| Bioprinting Plant Virus Nanoparticles for Immunotherapy and Relapse Prevention of Ovarian Cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,467,441 | July 1, 2020 | June 30, 2025 | STEINMETZ, NICOLE FRANZISKA | reporter.nih.gov |
| Multiplexed and dynamically targeted photoimmunotherapy of heterogeneous, chemoresistant micrometastases guided by online in vivo optical imaging of cell-surface biomarkers | NIH | National Cancer Institute | 2021 to 2024 | $2,446,812 | April 1, 2020 | March 31, 2026 | SPRING, BRYAN QUILTY | reporter.nih.gov |
| Novel DNA damage response therapeutics targeting replication protein A | NIH | National Cancer Institute | 2021 to 2025 | $2,445,263 | July 1, 2021 | June 30, 2027 | TURCHI, JOHN J. | reporter.nih.gov |
| Molecular Photoacoustic Imaging for Diagnostics and Therapy Monitoring | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2024 | $2,418,638 | August 1, 2020 | April 30, 2025 | BOUCHARD, RICHARD R. | reporter.nih.gov |
| Living Well: A Web-based Intervention to Improve Quality of Life in Rural and Urban Ovarian Cancer Survivors | NIH | National Cancer Institute | 2021 to 2024 | $2,382,410 | February 1, 2020 | January 31, 2026 | LUTGENDORF, SUSAN K | reporter.nih.gov |
| Tracking Peripheral T-Cell Repertoire Changes for Preoperative and Early Ovarian Cancer Diagnosis | NIH | National Cancer Institute | 2023 to 2025 | $2,290,302 | January 1, 2022 | December 31, 2026 | LI, BO | reporter.nih.gov |
| Defining the impact of stromal aging on ovarian cancer initiation | NIH | National Institute on Aging | 2021 to 2025 | $2,289,174 | September 30, 2021 | May 31, 2027 | COFFMAN, LAN | reporter.nih.gov |
| Discovery and development of Ku-targeted small molecule inhibitors: A novel mechanism of DNA-PK inhibition | NIH | National Cancer Institute | 2021 to 2024 | $2,285,280 | March 13, 2020 | February 28, 2026 | TURCHI, JOHN J. | reporter.nih.gov |
| Combined Methylation and Mutation to Predict Response to PARP Inhibitors | NIH | National Cancer Institute | 2021 to 2024 | $2,278,082 | April 1, 2020 | March 31, 2025 | SWISHER, ELIZABETH MARY | reporter.nih.gov |
| Proteomic Analyses of Serial Prediagnostic PLCO Serum in Cases and Controls to Identify Early Detection Ovarian Cancer Biomarkers Rising in a Substantial Fraction of Cases and Stable in Most Controls | NIH | National Cancer Institute | 2021 to 2025 | $2,274,536 | September 15, 2021 | August 31, 2026 | SKATES, STEVEN J | reporter.nih.gov |
| Tumor suppressor vulnerability conferred by aneuploid loss of haploinsufficient metallothionein genes | NIH | National Cancer Institute | 2022 to 2025 | $2,265,000 | September 1, 2025 | August 31, 2027 | DELANEY, JOE R | reporter.nih.gov |
| Targeting PKR-Bcl2 Signaling to Overcome Paclitaxel Resistance in Ovarian Cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,255,717 | August 1, 2022 | July 31, 2027 | DONG, JIXIN | reporter.nih.gov |
| Feasibility and Assessment of a Cascade Traceback Screening program - FACTS | NIH | National Cancer Institute | 2021 to 2023 | $2,213,234 | June 1, 2020 | May 31, 2025 | BUCHANAN, ADAM H | reporter.nih.gov |
| The role of multi-cellular aggregates vs. individual tumor cells in metastasis of high-grade serous ovarian cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,211,964 | August 7, 2020 | December 31, 2026 | KREEGER, PAMELA K | reporter.nih.gov |
| Chemo-mediated transcriptional reprogramming in ovarian cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,191,565 | September 23, 2022 | August 31, 2027 | ADLI, MAZHAR | reporter.nih.gov |
| Novel protein kinase signaling associated with platinum resistance in ovarian cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,175,190 | September 1, 2021 | August 31, 2027 | HUANG, SHUANG | reporter.nih.gov |
| Targeting CDK7 in high-grade serous ovarian carcinoma | NIH | National Cancer Institute | 2021 to 2025 | $2,172,899 | August 5, 2021 | July 31, 2027 | ZHANG, LIN | reporter.nih.gov |
| Exploiting markers of genomic instability in high-risk pre-invasive ovarian cancer | NIH | National Cancer Institute | 2023 to 2025 | $2,166,917 | June 6, 2023 | May 31, 2028 | SHAH, SOHRAB P | reporter.nih.gov |
| Expression of recombinant Fc receptors by engineered NK cells to enhance cancer cell killing | NIH | National Cancer Institute | 2021 to 2025 | $2,162,801 | January 1, 2016 | March 31, 2027 | WALCHECK, BRUCE K | reporter.nih.gov |
| Intravascular Delivery of Nanoclusters for Treatment of Deep-Seated Cancers with Magnetic Hyperthermia | NIH | National Cancer Institute | 2021 to 2024 | $2,150,799 | March 1, 2020 | February 28, 2026 | TARATULA, OLEH | reporter.nih.gov |
| Targeting Fanconi Anemia pathway to overcome platinum drug resistance in ovarian cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,140,462 | April 15, 2021 | March 31, 2027 | ZHU, WENGE | reporter.nih.gov |
| Development of a low-cost epigenetic screening assay for Pap specimen-based detection of early-stage ovarian cancer in high-risk women | NIH | National Cancer Institute | 2021 to 2025 | $2,125,930 | June 15, 2021 | May 31, 2027 | WANG, TZA-HUEI JEFF | reporter.nih.gov |
| Cancer-prone cell states of the fallopian tubal epithelium | NIH | National Cancer Institute | 2021 to 2025 | $2,108,907 | May 1, 2021 | April 30, 2027 | NIKITIN, ALEXANDER Y. | reporter.nih.gov |
| Enhancing endoplasmic reticulum stress in ovarian cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,102,493 | March 1, 2022 | February 29, 2028 | VADLAMUDI, RATNA K | reporter.nih.gov |
| Multimodal Imaging and Therapy of Ovarian Cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,083,778 | August 20, 2021 | July 31, 2027 | KUNDRA, VIKAS | reporter.nih.gov |
| Development of a novel small molecule RPN13 inhibitor and therapeutic for advanced ovarian cancer patients | NIH | National Cancer Institute | 2023 to 2024 | $2,047,415 | September 1, 2023 | August 31, 2025 | ANCHOORI, RAVI KUMAR | reporter.nih.gov |
| Coregistered Photoacoustic and Ultrasound Imaging for Ovarian Cancer Diagnosis and Risk Management | NIH | National Cancer Institute | 2021 to 2024 | $2,042,986 | January 1, 2020 | December 31, 2025 | ZHU, QUING | reporter.nih.gov |
| Nanoparticle-based Intraperitoneal Delivery of Combined Chemo-radiotherapy for Treatment of Ovarian Cancer Metastases | NIH | National Cancer Institute | 2022 to 2023 | $2,025,186 | September 11, 2019 | July 31, 2025 | JAY, MICHAEL | reporter.nih.gov |
| Epigenetic Drug Regimens for Homologous Recombination Proficient Ovarian Cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,013,891 | July 1, 2020 | February 28, 2026 | KHABELE, DINEO | reporter.nih.gov |
| Probabilistic Multiscale Modeling of the Tumor Microenvironment | NIH | National Cancer Institute | 2023 to 2025 | $2,001,618 | January 1, 2023 | December 31, 2027 | TANSEY, WESLEY | reporter.nih.gov |
| A novel and effective immunotherapeutic approach for tumors with a low mutational load and few tumor-infiltrating lymphocytes, such as ovarian cancer | NIH | National Cancer Institute | 2021 to 2022 | $2,000,000 | July 9, 2020 | December 31, 2022 | SESSIONS, JENNIFER JUNE | reporter.nih.gov |
| Instantaneous Tumor Spray for Real-Time Surgical Guidance | NIH | National Cancer Institute | 2022 to 2023 | $1,998,821 | September 1, 2022 | August 31, 2025 | GRAY, BRIAN DAVID | reporter.nih.gov |
| Targeting Wnt signaling in therapy-resistant ovarian cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,998,601 | July 9, 2021 | June 30, 2026 | BITLER, BENJAMIN G | reporter.nih.gov |
| Development of a first-in-class combination of DNA damage response inhibitors for the treatment of high-grade serous ovarian cancer | NIH | National Cancer Institute | 2023 to 2024 | $1,996,571 | February 10, 2023 | January 31, 2026 | GILAD, OREN | reporter.nih.gov |
| Characterizing non-coding somatic and germline variant interactions in ovarian cancer | NIH | National Cancer Institute | 2021 to 2023 | $1,994,900 | June 1, 2020 | May 31, 2024 | GAYTHER, SIMON ANDREW | reporter.nih.gov |
| Testing a Low Cost Population- and Theory-Based Outreach Intervention to Engage Ovarian Cancer Survivors and their Close Relatives to Consider Genetic Services | NIH | National Cancer Institute | 2021 to 2023 | $1,991,480 | May 1, 2020 | April 30, 2025 | GUAN, YUE | reporter.nih.gov |
| Regulation of DNA synthesis in response to DNA damage | NIH | National Cancer Institute | 2021 to 2025 | $1,988,550 | December 1, 2015 | November 30, 2025 | CICCIA, ALBERTO | reporter.nih.gov |
| Development and application of a scalable workflow for immunomagnetic separation of exRNA carrier subclasses and molecular analysis of their cargo | NIH | National Cancer Institute | 2021 to 2022 | $1,987,082 | September 1, 2019 | August 31, 2024 | LAURENT, LOUISE CHANG | reporter.nih.gov |
| Blood-Based Biomarkers for Personalized Risk Assessment of Breast and Ovarian Cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,983,279 | September 1, 2023 | August 31, 2028 | FAHRMANN, JOHANNES F | reporter.nih.gov |
| Nanosensor Array Platform to Capture Whole Disease Fingerprints | NIH | National Institute of Biomedical Imaging and Bioengineering | 2023 to 2025 | $1,980,516 | June 15, 2023 | April 30, 2027 | HELLER, DANIEL ALAN | reporter.nih.gov |
| 3D Spatial Multi-Omics Profiling of Ovarian Cancer | NIH | National Cancer Institute | 2024 to 2025 | $1,979,214 | September 1, 2024 | August 31, 2029 | MOK, SAMUEL C | reporter.nih.gov |
| Novobiocin-mediated polymerase theta inhibition in homologous recombination repair-deficient cancers | NIH | National Cancer Institute | 2022 to 2025 | $1,976,994 | September 1, 2022 | August 31, 2027 | SHAPIRO, GEOFFREY I. | reporter.nih.gov |
| High-content High-speed Chemical Imaging of Metabolic Reprogramming by Integration of Advanced Instrumentation and Data Science | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2025 | $1,976,184 | April 1, 2022 | December 31, 2026 | CHENG, JI-XIN | reporter.nih.gov |
| Optimizing theranostic radiopharmaceutical therapy to combat resistance to PARP inhibition in advanced ovarian cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,970,274 | May 31, 2023 | April 30, 2028 | FARWELL, MICHAEL DAVID | reporter.nih.gov |
| Differentiation and Function of Monocytes and Macrophages | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,968,750 | September 15, 2011 | November 30, 2026 | RANDOLPH, GWENDALYN J | reporter.nih.gov |
| Leveraging tumor registries and pathology specimens to facilitate genetic testing and traceback for ovarian cancer | NIH | National Cancer Institute | 2021 to 2023 | $1,967,027 | March 1, 2020 | February 28, 2025 | HUNTER, JESSICA EZZELL | reporter.nih.gov |
| SERS diagnostics platform for liquid bioapsy analysis of tumor-associated exosomes | NIH | National Cancer Institute | 2021 to 2024 | $1,960,132 | April 15, 2020 | March 31, 2025 | CARNEY, RANDY | reporter.nih.gov |
| Profiling the Fluid Assisted Dissemination of Pre-malignant cells in Fallopian Tubes | NIH | National Cancer Institute | 2023 to 2025 | $1,952,343 | July 7, 2023 | June 30, 2028 | MEHTA, GEETA | reporter.nih.gov |
| UBR5's mechanisms of action in tumorigenesis and immunoregulation | NIH | National Cancer Institute | 2023 to 2025 | $1,932,924 | March 1, 2023 | February 29, 2028 | MA, XIAOJING | reporter.nih.gov |
| Methylomic basis of survival disparities among Black and White women with high-grade serous ovarian cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,926,403 | January 1, 2023 | December 31, 2027 | PERES, LAUREN COLE | reporter.nih.gov |
| Clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,914,421 | May 1, 2023 | April 30, 2028 | SWISHER, ELIZABETH MARY | reporter.nih.gov |
| Assessing DNA polymerase theta as a therapeutic target in BRCA1 mutant cancer | NIH | National Cancer Institute | 2022 to 2025 | $1,890,097 | March 1, 2022 | February 28, 2027 | JOHNSON, NEIL | reporter.nih.gov |
| A phase I/II study of combined therapy with Th17-inducing dendritic cells and pembrolizumab in patients with recurrent epithelial ovarian cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,881,216 | July 1, 2023 | June 30, 2028 | KNUTSON, KEITH L. | reporter.nih.gov |
| Novel therapeutics for targeting checkpoint dysfunction in cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,865,672 | December 15, 2016 | January 31, 2027 | LIN, WEEI-CHIN | reporter.nih.gov |
| Regulation of repetitive elements in cancer by P53 and epigenetic mechanisms | NIH | National Cancer Institute | 2021 to 2025 | $1,844,213 | April 14, 2021 | March 31, 2026 | CHIAPPINELLI, KATHERINE B | reporter.nih.gov |
| Dissecting FAK-regulated oncogenic signaling programs in ovarian cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,837,271 | May 1, 2020 | April 30, 2026 | SCHLAEPFER, DAVID D | reporter.nih.gov |
| Lipid Metabolism Switch Triggers Invasive and Chemoresistant Epithelial Ovarian Cancer Phenotype | NIH | National Cancer Institute | 2022 to 2025 | $1,815,947 | August 9, 2022 | July 31, 2027 | DAWSON, MICHELLE R | reporter.nih.gov |
| The Hippo Signaling Pathway in High Grade Serous Ovarian Carcinoma | NIH | National Cancer Institute | 2021 to 2025 | $1,811,794 | May 1, 2016 | August 31, 2026 | WANG, CHENG | reporter.nih.gov |
| Nanotechnology-based personalized treatment of metastatic ovarian cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,811,714 | June 3, 2022 | May 31, 2027 | MINKO, TAMARA | reporter.nih.gov |
| Mucins and immune cell interactions in ovarian cancer pathogenesis & progression | NIH | National Cancer Institute | 2021 to 2022 | $1,809,110 | March 1, 2016 | February 29, 2024 | CRAMER, DANIEL WILLIAM | reporter.nih.gov |
| Computational analysis of tumor ecosystems and their regulation and association with outcomes | NIH | National Cancer Institute | 2023 to 2025 | $1,807,708 | May 1, 2023 | April 30, 2028 | GENTLES, ANDREW J. | reporter.nih.gov |
| Elucidating a novel WNT4 regulatory axis as a driver of gynecologic cancer health disparities | NIH | National Cancer Institute | 2023 to 2025 | $1,807,191 | September 21, 2023 | August 31, 2028 | SIKORA, MATTHEW J | reporter.nih.gov |
| Sensitizing Ovarian Cancer To PARP inhibitor and platinum treatment | NIH | National Cancer Institute | 2021 to 2025 | $1,785,830 | June 1, 2021 | May 31, 2026 | LOU, ZHENKUN | reporter.nih.gov |
| Mechanoimmunological interactions between TCR-T cells and tumor fibrotic microenvironment | NIH | National Cancer Institute | 2023 to 2025 | $1,784,080 | May 9, 2023 | April 30, 2028 | ZHAO, RUOGANG | reporter.nih.gov |
| ALDH Inhibition as Modulator of Tumor Immunobiology | NIH | National Cancer Institute | 2021 to 2024 | $1,780,049 | May 1, 2020 | April 30, 2026 | BUCKANOVICH, RONALD J | reporter.nih.gov |
| Improving Treatment Selection in Advanced Ovarian Cancer | NIH | National Cancer Institute | 2022 to 2025 | $1,780,014 | April 6, 2022 | May 31, 2025 | PANDHARIPANDE, PARI VIJAY | reporter.nih.gov |
| Premenopausal bilateral oophorectomy and biomarkers of Alzheimer’s and cerebrovascular diseases | NIH | National Institute on Aging | 2025 | $1,775,401 | May 15, 2025 | April 30, 2030 | KANTARCI, KEJAL | reporter.nih.gov |
| NAD+ metabolism in PARP inhibitor resistance of ovarian cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,775,030 | June 15, 2021 | September 30, 2026 | KANAKKANTHARA, ARUN | reporter.nih.gov |
| Dissecting the interaction between DNA damage repair defects and the tumor microenvironment | NIH | Office of the Director, National Institutes of Health | 2021 to 2024 | $1,770,000 | September 16, 2020 | August 31, 2025 | HILL, SARAH JAMES | reporter.nih.gov |
| POTENTIATION OF ANTI-TUMOR IMMUNITY BY ONCOLYTIC VIRUS IN SITU VACCINATION | NIH | National Cancer Institute | 2023 to 2025 | $1,766,542 | April 1, 2023 | March 31, 2028 | ZAMARIN, DMITRIY | reporter.nih.gov |
| Preclinical development of CM-CX1 for the treatment of ovarian clear cell and renal cell carcinomas | NIH | National Cancer Institute | 2021 to 2023 | $1,756,207 | September 8, 2021 | August 31, 2025 | MURAD, JOANA M | reporter.nih.gov |
| Reverse Engineering the Extracellular Neighborhood to Support the Functional Tissue Unit: A Use Case to Restore Ovarian Function | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2025 | $1,753,326 | August 24, 2022 | July 31, 2026 | LARONDA, MONICA M | reporter.nih.gov |
| Deep Ovarian Cancer Metabolomics | NIH | National Cancer Institute | 2021 to 2025 | $1,737,416 | September 20, 2018 | July 31, 2029 | FERNANDEZ, FACUNDO MARTIN | reporter.nih.gov |
| Immunometabolic Programs Controlled by ER Stress in Cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,730,884 | July 1, 2023 | June 30, 2028 | CUBILLOS-RUIZ, JUAN R | reporter.nih.gov |
| Mechanisms of Selective Therapeutic Synergy of PARP-inhibition and CTLA4 Blockade Engaged by Interferon-gamma in the Ovarian Tumor Microenvironment | NIH | National Cancer Institute | 2021 to 2025 | $1,728,023 | February 18, 2019 | January 31, 2026 | ADAMS, SARAH FOSTER | reporter.nih.gov |
| Targeting RNA Polymerase I Transcription Machinery in Chemoresistant Ovarian Cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,726,558 | March 1, 2020 | February 28, 2026 | LANDEN, CHARLES NICHOLSON | reporter.nih.gov |
| Characterization of high-grade serous ovarian cancer subtypes via single-cell profiling | NIH | National Cancer Institute | 2021 to 2024 | $1,720,475 | April 1, 2019 | March 31, 2026 | GREENE, CASEY S | reporter.nih.gov |
| Normalizing aberrant metabolism in ovarian cancer by a unique drug delivery system | NIH | National Cancer Institute | 2021 to 2025 | $1,716,310 | January 1, 2021 | December 31, 2026 | MUKHERJEE, PRIYABRATA | reporter.nih.gov |
| Development of Claudin MAbs for Treating Solid Tumors | NIH | National Cancer Institute | 2022 to 2024 | $1,703,866 | June 1, 2022 | November 30, 2024 | RUCKER, JOSEPH BENJAMIN | reporter.nih.gov |
| Role of the pro-inflammatory omental microenvironment in ovarian cancer progression | NIH | National Cancer Institute | 2022 to 2025 | $1,700,150 | May 3, 2022 | April 30, 2027 | AU YEUNG, CHI LAM | reporter.nih.gov |
| Imaging mass spectrometry methodologies for studying the metabolites of cancer metastasis | NIH | National Cancer Institute | 2021 to 2024 | $1,697,798 | May 1, 2020 | April 30, 2026 | BURDETTE, JOANNA E | reporter.nih.gov |
| Induction of autosis to overcome resistance in adoptive cell therapy for solid tumors | NIH | National Cancer Institute | 2023 to 2025 | $1,691,813 | April 1, 2023 | March 31, 2028 | LU, YONG | reporter.nih.gov |
| Uncovering the Mechanisms of Metastasis in Fallopian Tube-Originated Ovarian Cancer | NIH | National Cancer Institute | 2022 to 2025 | $1,677,880 | June 17, 2022 | April 30, 2027 | YANG-HARTWICH, YANG | reporter.nih.gov |
| Targeting Fluid Stress-induced Chemoresistance in a 3D Carcinomatosis Perfusion Model Using Mechanism-based Photo-immunoconjugate Nanoparticles | NIH | National Cancer Institute | 2023 to 2025 | $1,630,012 | January 12, 2023 | December 31, 2027 | HUANG, HUANG CHIAO | reporter.nih.gov |
| Alternative NF-kB activation in post-chemotherapy setting to elucidate novel mechanisms of ovarian cancer relapse | NIH | National Cancer Institute | 2022 to 2025 | $1,622,419 | September 1, 2022 | August 31, 2027 | HOUSE, CARRIE DANIELLE | reporter.nih.gov |
| Iron, Ferroptosis and Ovarian Cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,622,232 | September 16, 2014 | June 30, 2026 | TORTI, SUZY V | reporter.nih.gov |
| The NYU Women's Health Study | NIH | National Cancer Institute | 2021 to 2023 | $1,621,115 | May 1, 2015 | April 30, 2025 | CHEN, YU | reporter.nih.gov |
| Reprogramming the Tumor Microenvironment in Ovarian Cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,615,239 | July 3, 2020 | June 30, 2025 | SCHLAEPFER, DAVID D | reporter.nih.gov |
| HTS for the discovery of activators of NK cell cytotoxicity | NIH | National Cancer Institute | 2021 to 2025 | $1,613,616 | June 1, 2021 | May 31, 2026 | WALD, DAVID | reporter.nih.gov |
| Targeting ovarian cancer spheroid formation and metabolic adaptation by APJ inhibition | NIH | National Cancer Institute | 2022 to 2025 | $1,613,192 | December 1, 2021 | November 30, 2026 | WOO, SUKYUNG | reporter.nih.gov |
| RNA-Binding Proteins as Molecular Integrators that Control the Response of HGSOC to Ant-Cancer Therapies | NIH | National Cancer Institute | 2021 to 2023 | $1,598,760 | December 7, 2018 | November 30, 2024 | YAFFE, MICHAEL B | reporter.nih.gov |
| Role of ALDH in PARP inhibitor resistance in HR-deficient ovarian cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,596,420 | May 1, 2021 | April 30, 2027 | WANG, QIEN | reporter.nih.gov |
| Fractionated photoimmunotherapy to harness low-dose immunostimulation in ovarian cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,556,256 | July 1, 2023 | June 30, 2028 | SPRING, BRYAN QUILTY | reporter.nih.gov |
| Signaling basis of senescence-associated secretory phenotype and its implications in epithelial ovarian cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,538,451 | August 2, 2023 | July 31, 2028 | ZHANG, RUGANG | reporter.nih.gov |
| Role of exosomal SPHK1 in ovarian cancer progression | NIH | National Cancer Institute | 2022 to 2025 | $1,526,550 | February 1, 2022 | January 31, 2027 | PRADEEP, SUNILA | reporter.nih.gov |
| A novel more effective genotoxic therapy for ovarian cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,512,918 | March 1, 2023 | February 28, 2026 | SIMPKINS, FIONA | reporter.nih.gov |
| Modeling Factors Associated with Risk of High-Grade Serous Carcinoma in Mice | NIH | National Cancer Institute | 2021 to 2023 | $1,504,662 | January 1, 2019 | December 31, 2023 | CHO, KATHLEEN R. | reporter.nih.gov |
| Novel Biomarkers Predicting Blood Clots in Ovarian Cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,495,349 | September 19, 2023 | July 31, 2028 | AFSHAR-KHARGHAN, VAHID | reporter.nih.gov |
| Targeting sideroflexin 4, a mitochondrial inner membrane protein involved iniron sulfur cluster biogenesis, to enhance the efficacy of DNA-damaging drugs inovarian cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,466,837 | December 1, 2019 | November 30, 2025 | TORTI, SUZY V | reporter.nih.gov |
| Dissecting BRCA1-PALB2 Activity in DNA Repair and Development | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $1,452,865 | August 5, 2020 | July 31, 2024 | JOHNSON, NEIL | reporter.nih.gov |
| Platelets promote growth of ovarian cancer | NIH | National Cancer Institute | 2021 to 2023 | $1,447,929 | August 1, 2013 | November 30, 2024 | AFSHAR-KHARGHAN, VAHID | reporter.nih.gov |
| Randomized trial of REVITALIZE: A telehealth intervention to reduce fatigue interference among adults with advanced ovarian cancer on PARP inhibitors | NIH | National Cancer Institute | 2024 to 2025 | $1,433,938 | June 1, 2024 | May 31, 2029 | WRIGHT, ALEXI A | reporter.nih.gov |
| Synthesis and evaluation of BTN3A1 ligands for cancer immunotherapy | NIH | National Cancer Institute | 2022 to 2025 | $1,423,030 | May 1, 2022 | April 30, 2027 | WIEMER, ANDREW J | reporter.nih.gov |
| FOXL2 in Adult Granulosa Cell Tumorigenesis | NIH | National Cancer Institute | 2021 to 2024 | $1,413,079 | June 1, 2020 | May 31, 2025 | SHIMASAKI, SHUNICHI | reporter.nih.gov |
| B cell-dependent anti-tumor immunity in ovarian cancer | NIH | National Cancer Institute | 2021 to 2022 | $1,407,712 | September 20, 2018 | January 29, 2023 | CONEJO-GARCIA, JOSE R | reporter.nih.gov |
| Targeting PP4 to improve ovarian cancer response to immunotherapy | NIH | National Cancer Institute | 2023 to 2025 | $1,403,025 | August 3, 2023 | July 31, 2028 | CURTIS, MARION | reporter.nih.gov |
| Targeting alternative isoform variation for TCR discovery in platinum-resistant ovarian cancer | NIH | National Cancer Institute | 2024 to 2025 | $1,377,341 | June 18, 2024 | May 31, 2029 | MEMARZADEH, SANAZ | reporter.nih.gov |
| Developing biomarkers of response for a new therapy in ovarian cancer | NIH | National Cancer Institute | 2024 to 2025 | $1,369,387 | February 15, 2024 | December 31, 2028 | SIMPKINS, FIONA | reporter.nih.gov |
| Compensatory Mechanisms that Promote Homologous Recombination in BRCA1 Mutant Cancers | NIH | National Cancer Institute | 2021 to 2025 | $1,367,763 | September 12, 2017 | August 31, 2029 | JOHNSON, NEIL | reporter.nih.gov |
| Methodologic Innovations in Cancer Epidemiology | NIH | National Cancer Institute | 2023 to 2025 | $1,359,433 | March 1, 2023 | February 28, 2027 | ROSNER, BERNARD A | reporter.nih.gov |
| High-throughput Epigenomic Mapping of Regulatory Elements in Ovarian Cancer at Basepair Resolution | NIH | National Cancer Institute | 2021 to 2024 | $1,355,592 | July 1, 2018 | July 31, 2025 | SHEN, HUI | reporter.nih.gov |
| Determining the mechanisms by which calorie restriction alters macrophage polarization to promote an anti-tumor environment in epithelial ovarian cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,346,091 | May 1, 2020 | April 30, 2026 | RATTAN, RAMANDEEP | reporter.nih.gov |
| The role of biobehavioral factors and anti-inflammatory medications on the ovarian tumor immune response | NIH | National Cancer Institute | 2023 to 2025 | $1,341,086 | April 1, 2024 | March 31, 2029 | TWOROGER, SHELLEY S | reporter.nih.gov |
| Cancer cell selective killing nanoparticle for advanced ovarian cancer treatment | NIH | National Cancer Institute | 2022 to 2025 | $1,330,329 | August 9, 2022 | July 31, 2027 | XU, PEISHENG | reporter.nih.gov |
| RAD51 paralog function in cancer predisposition and genome integrity | NIH | National Institute of Environmental Health Sciences | 2023 to 2025 | $1,330,198 | December 1, 2022 | February 28, 2027 | BERNSTEIN, KARA A | reporter.nih.gov |
| Metabolic basis of ARID1A-mutated ovarian cancer | NIH | National Cancer Institute | 2022 to 2025 | $1,322,798 | August 1, 2022 | November 30, 2027 | ZHANG, RUGANG | reporter.nih.gov |
| Early Detection through Novel OCEAN Technology - Ovarian Cancer Exosomal Analysis with Nanoplasmonics | NIH | National Cancer Institute | 2021 to 2022 | $1,320,224 | September 1, 2018 | July 31, 2024 | LEE, HAKHO | reporter.nih.gov |
| Spatial and Bayesian modeling methods for assessment of the tumor immune microenvironment and survival of women with ovarian cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,312,539 | May 1, 2023 | April 30, 2028 | FRIDLEY, BROOKE L | reporter.nih.gov |
| Regulation of mitochondrial redox homeostasis and signaling in metastatic ovarian cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,311,408 | July 1, 2021 | March 31, 2026 | HEMPEL, NADINE | reporter.nih.gov |
| Delivery of cytokines for cancer immunotherapy using nanolayer-controlled trafficking of liposomal nanoparticles | NIH | National Cancer Institute | 2021 to 2025 | $1,306,449 | July 1, 2019 | January 31, 2030 | HAMMOND, PAULA T | reporter.nih.gov |
| Mechanisms of radioresistance and strategies for radiosensitization in ovarian clear cell carcinoma | NIH | National Cancer Institute | 2021 to 2025 | $1,295,411 | August 16, 2016 | July 31, 2027 | PENG, GUANG | reporter.nih.gov |
| Stem cell-derived exosomes to ameliorate chemobrain | NIH | National Cancer Institute | 2023 to 2025 | $1,294,957 | March 13, 2023 | February 29, 2028 | ACHARYA, MUNJAL M | reporter.nih.gov |
| Anti-vascular and cytotoxic nanoparticle formulations for ovarian cancer therapy | NIH | National Cancer Institute | 2021 to 2023 | $1,291,250 | August 1, 2019 | August 31, 2024 | MIESZAWSKA, ANETA JOANNA | reporter.nih.gov |
| Common biology underlying pleiotropic breast, prostate and ovarian cancer risk loci | NIH | National Cancer Institute | 2022 to 2023 | $1,291,109 | September 1, 2022 | July 31, 2024 | GAYTHER, SIMON ANDREW | reporter.nih.gov |
| Genomic Analysis of Inherited Breast and Ovarian Cancer | NIH | National Cancer Institute | 2024 to 2025 | $1,290,392 | August 1, 2024 | July 31, 2029 | KING, MARY-CLAIRE | reporter.nih.gov |
| Evaluating unique aspects of quiescent ovarian cancer cell biology for therapeutic targets | NIH | National Cancer Institute | 2023 to 2025 | $1,287,038 | July 15, 2023 | June 30, 2028 | BUCKANOVICH, RONALD J | reporter.nih.gov |
| Immunological consequences of LINE-1 expression in cancer | NIH | National Cancer Institute | 2024 to 2025 | $1,281,087 | April 1, 2024 | March 31, 2029 | CHIAPPINELLI, KATHERINE B | reporter.nih.gov |
| Targeting RANKL for the treatment of muscle and bone defects in cachexia | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2025 | $1,279,154 | December 10, 2022 | November 30, 2026 | BONETTO, ANDREA | reporter.nih.gov |
| PCOS and androgen-related disease modeling and drug testing in Multi-organ Integrated Microfluidic Reproductive Platform | NIH | National Institute of Environmental Health Sciences | 2021 | $1,261,686 | September 15, 2019 | August 31, 2023 | KIM, JI-YONG JULIE | reporter.nih.gov |
| B55 alpha deficiency as a therapeutic target in cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,261,643 | June 1, 2020 | May 31, 2025 | ZHANG, JUNRAN | reporter.nih.gov |
| Mitigate cisplatin induced acute kidney injury through preservation of vasculature and proximal tubule | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2024 | $1,254,853 | April 1, 2021 | March 31, 2026 | PAN, HUA | reporter.nih.gov |
| Macrocyclic Peptidyl Inhibitors of NEMO-IKK Interaction | NIH | National Cancer Institute | 2021 to 2023 | $1,247,018 | July 1, 2019 | June 30, 2026 | PEI, DEHUA | reporter.nih.gov |
| Ionizing Radiation-Induced DNA damage repair | NIH | National Cancer Institute | 2021 to 2023 | $1,245,640 | May 1, 2009 | August 31, 2025 | LIU, YILUN | reporter.nih.gov |
| Glycomics Laboratory for the Development of Ovarian Cancer Biomarkers | NIH | National Cancer Institute | 2021 to 2022 | $1,239,339 | November 10, 2020 | November 30, 2022 | ABBOTT, KAREN L. | reporter.nih.gov |
| Targeting p53 conformational defects to arrest carcinogenesis | NIH | National Cancer Institute | 2021 to 2023 | $1,236,632 | July 1, 2019 | June 30, 2025 | SORAGNI, ALICE | reporter.nih.gov |
| Repurposing Atovaquone for Preventing Ovarian Cancer: An Example of Successful Inhibition of Oxidative Phosphorylation | NIH | National Cancer Institute | 2021 to 2024 | $1,224,133 | May 11, 2020 | April 30, 2026 | BARROILHET, LISA M | reporter.nih.gov |
| Ovarian Cancer Epigenetics, Immunity and Therapy | NIH | National Cancer Institute | 2021 to 2022 | $1,218,811 | July 1, 2018 | June 30, 2023 | ZOU, WEIPING | reporter.nih.gov |
| The contribution of RAD51C and RAD51D to breast and ovarian cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,217,733 | May 1, 2018 | November 30, 2024 | COUCH, FERGUS JOSEPH | reporter.nih.gov |
| Exploiting gold nanoparticle as a probe to identify therapeutic targets | NIH | National Cancer Institute | 2022 to 2025 | $1,212,885 | December 15, 2021 | November 30, 2027 | MUKHERJEE, PRIYABRATA | reporter.nih.gov |
| Role of Sox2 in Stress Adaptations to Ovarian Cancer Anchorage Independence | NIH | National Cancer Institute | 2021 to 2023 | $1,194,290 | August 12, 2021 | March 31, 2024 | HEMPEL, NADINE | reporter.nih.gov |
| Decoupling acute toxicities and antitumor efficacy in adoptive cell therapy | NIH | National Cancer Institute | 2024 to 2025 | $1,194,123 | May 1, 2024 | April 30, 2029 | LU, YONG | reporter.nih.gov |
| A Novel Therapeutic Strategy for Ovarian Cancer | NIH | National Cancer Institute | 2022 to 2023 | $1,185,015 | March 8, 2022 | February 29, 2024 | HERGENROTHER, PAUL | reporter.nih.gov |
| The Role of Egfl6 in Tumor Immunity | NIH | National Cancer Institute | 2023 to 2025 | $1,182,281 | June 7, 2023 | May 31, 2028 | CASCIO, SANDRA | reporter.nih.gov |
| Mapping Cancer Metabolism by Mid-infrared Photothermal Microscopy | NIH | National Cancer Institute | 2021 to 2023 | $1,174,798 | September 20, 2021 | August 31, 2025 | CHENG, JI-XIN | reporter.nih.gov |
| Cellular Immunotherapy of Ovarian Cancer | NIH | National Cancer Institute | 2021 to 2023 | $1,169,521 | September 1, 2019 | August 31, 2024 | DOTTI, GIANPIETRO | reporter.nih.gov |
| Clinical platform for high-throughput analyses of extracellular vesicles | NIH | National Cancer Institute | 2021 to 2022 | $1,161,669 | August 2, 2018 | July 31, 2024 | LEE, HAKHO | reporter.nih.gov |
| Targeting Lipid Unsaturation in Ovarian Cancer Stem Cells | NIH | National Cancer Institute | 2021 to 2022 | $1,158,147 | August 1, 2018 | July 31, 2024 | MATEI, DANIELA E | reporter.nih.gov |
| Stem Cell-based Platform for Targeted Enzyme/Prodrug Therapy of Recurrent Ovarian Cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,142,655 | April 1, 2021 | March 31, 2027 | HATEFI, ARASH | reporter.nih.gov |
| Sensitizing high grade serous cancers to immunotherapy through the induction of DNA damage | NIH | National Cancer Institute | 2022 to 2024 | $1,141,919 | July 1, 2020 | June 30, 2026 | MCLEAN, KAREN | reporter.nih.gov |
| A Novel Symbiotic Approach for Ovarian Cancer | NIH | National Cancer Institute | 2021 to 2023 | $1,141,502 | June 1, 2019 | May 31, 2026 | TUSHIR-SINGH, JOGENDER | reporter.nih.gov |
| Optimizing PARP inhibitor therapy through novel approaches to resolve the molecular mechanisms of response | NIH | National Cancer Institute | 2021 to 2023 | $1,140,163 | August 1, 2019 | July 31, 2025 | DUBACH, JOHN | reporter.nih.gov |
| Interrogating MRCK Protein Kinases in Ovarian Cancer | NIH | National Cancer Institute | 2024 to 2025 | $1,138,820 | March 1, 2024 | February 28, 2029 | DUNCAN, JAMES STUART | reporter.nih.gov |
| Biomedical Applications of Expanded Porphyrins | NIH | National Cancer Institute | 2021 to 2025 | $1,129,583 | August 1, 1990 | April 30, 2029 | SESSLER, JONATHAN L | reporter.nih.gov |
| Novel role of APOBEC3 enzymes as key mediators of cisplatin sensitivity through aberrant processing of interstrand crosslinks | NIH | National Cancer Institute | 2021 to 2024 | $1,127,074 | April 1, 2019 | March 31, 2026 | PATRICK, STEVE M | reporter.nih.gov |
| Genomic and Transcriptomic Analysis of Breast and Ovarian Cancers | NIH | National Cancer Institute | 2021 to 2022 | $1,117,541 | February 1, 2018 | January 31, 2025 | SCHILDKRAUT, JOELLEN M. | reporter.nih.gov |
| Acquisition of OrbiTrap Eclipse w/FAIMS mass spectrometer | NIH | Office of the Director, National Institutes of Health | 2022 | $1,100,563 | July 1, 2022 | June 30, 2023 | GAFKEN, PHILIP R | reporter.nih.gov |
| Molecular mechanism and preclinical development of BETi and PARPi combination therapy | NIH | National Cancer Institute | 2021 to 2023 | $1,090,132 | February 1, 2019 | January 31, 2025 | ZHANG, LIN | reporter.nih.gov |
| Oral Epigallocatechin Gallate (EGCG) for Treatment of Cisplatin Ototoxicity | NIH | National Institute on Deafness and Other Communication Disorders | 2021 to 2022 | $1,085,419 | June 1, 2018 | May 31, 2025 | RYBAK, LEONARD P | reporter.nih.gov |
| Targeting DNA Ligase I in Ovarian Cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,084,219 | June 1, 2023 | May 31, 2028 | TOMKINSON, ALAN E | reporter.nih.gov |
| Hedgehog/Gli1-targeted therapies to overcome ovarian cancer chemoresistance and disease recurrence | NIH | National Cancer Institute | 2021 to 2023 | $1,069,550 | February 15, 2018 | July 31, 2025 | PALLE, KOMARAIAH | reporter.nih.gov |
| TUMOR SPECIFIC DELIVERY OF VERTICILLIN A OVERCOMES EPIGENETIC SILENCING RESPONSIBLE FOR DRUG RESISTANCE | NIH | National Cancer Institute | 2021 to 2022 | $1,063,657 | April 1, 2018 | March 31, 2024 | GRINSTAFF, MARK W. | reporter.nih.gov |
| Protein arginine methyltransferase inhibitors in treatment of high-grade serous ovarian cancer and triple-negative breast cancer | NIH | National Cancer Institute | 2024 to 2025 | $1,061,394 | August 29, 2024 | July 31, 2029 | ZHANG, LIN | reporter.nih.gov |
| Examining the role of the miR-181a:Wnt/B-catenin axis in ovarian cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,056,704 | April 1, 2016 | March 31, 2028 | DIFEO, ANALISA VIRGINIA | reporter.nih.gov |
| Role of RNA activation in Tumor Progression and Metastasis | NIH | National Cancer Institute | 2021 to 2023 | $1,054,998 | September 10, 2019 | August 31, 2025 | CHALUVALLY-RAGHAVAN, PRADEEP | reporter.nih.gov |
| Deciphering the mechanism underlying BRCA1 breast cancer development | NIH | National Cancer Institute | 2021 | $1,053,423 | August 7, 2019 | February 28, 2023 | LIVINGSTON, DAVID MORSE | reporter.nih.gov |
| Protein Nutrition in Experimental Uremia | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,052,625 | September 1, 1987 | June 30, 2028 | HU, ZHAOYONG | reporter.nih.gov |
| Developing PARP-1 PET with companion tissue assay as a precision tool to guide PARPi therapy | NIH | National Cancer Institute | 2024 to 2025 | $1,048,112 | January 5, 2024 | December 31, 2028 | MCDONALD, ELIZABETH | reporter.nih.gov |
| PQ#12; Targeting Nampt-mediated NAD+ metabolism in chemobrain | NIH | National Cancer Institute | 2022 to 2023 | $1,044,715 | August 8, 2019 | July 31, 2025 | JANG, MI-HYEON | reporter.nih.gov |
| Mechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancer | NIH | National Cancer Institute | 2022 to 2025 | $1,041,302 | December 1, 2015 | January 31, 2027 | ZHANG, RUGANG | reporter.nih.gov |
| Restoring genome stability and tumor suppression in BRCA1 deficient cells | NIH | National Cancer Institute | 2021 to 2022 | $1,036,531 | January 1, 2019 | December 31, 2023 | BAER, RICHARD J | reporter.nih.gov |
| SBIR: In vivo engineering of B7-H3.CAR-T cells for ovarian cancer therapy | NIH | National Cancer Institute | 2025 | $1,031,566 | September 11, 2025 | August 31, 2027 | YANG, MING | reporter.nih.gov |
| Engineered ECM platforms to analyze progression in high grade serous ovarian cancer | NIH | National Cancer Institute | 2021 to 2022 | $1,026,038 | September 1, 2018 | August 31, 2023 | KREEGER, PAMELA K | reporter.nih.gov |
| SUPPORT SERVICES FOR THE PLCO ETIOLOGIC&EARLY MARKER STUDIES (PLCO EEMS) | NIH | National Cancer Institute | 2021 | $1,024,263 | July 20, 2020 | July 19, 2021 | RILEY, THOMAS | reporter.nih.gov |
| The Function of EGFL6 in Ovarian Cancer Cell Biology, Tumor Initiation, and Therapy | NIH | National Cancer Institute | 2021 to 2023 | $1,016,872 | December 1, 2018 | November 30, 2023 | BUCKANOVICH, RONALD J | reporter.nih.gov |
| Inhibin function in tumor angiogenesis | NIH | National Cancer Institute | 2021 to 2023 | $1,013,299 | July 1, 2018 | December 31, 2024 | KARTHIKEYAN, MYTHREYE | reporter.nih.gov |
| The Immunomodulatory Function of Cyclin E1 in Ovarian Cancer and Therapeutic Targeting | NIH | National Cancer Institute | 2024 to 2025 | $1,011,702 | April 1, 2024 | March 31, 2029 | DING, LIYA | reporter.nih.gov |
| Investigating PolQ-mediated alternative NHEJ in breast cancer | NIH | National Cancer Institute | 2021 to 2023 | $997,276 | June 10, 2021 | January 31, 2026 | SFEIR, AGNEL | reporter.nih.gov |
| Engineering recombinase circuits for cellular diagnostic devices | NIH | National Institute of Biomedical Imaging and Bioengineering | 2024 to 2025 | $988,438 | August 1, 2024 | April 30, 2028 | WONG, WILSON | reporter.nih.gov |
| Curation Expert Panels for BRCA1/2 and Hereditary Breast, Ovarian and Pancreatic (HBOP) Cancer Genes | NIH | National Cancer Institute | 2022 to 2025 | $987,571 | August 10, 2022 | July 31, 2028 | COUCH, FERGUS JOSEPH | reporter.nih.gov |
| Fluorescence tomography plugin unit for spatial monitoring of T cell migration | NIH | National Cancer Institute | 2021 | $969,173 | September 17, 2019 | May 31, 2024 | KLOSE, ALEXANDER D. | reporter.nih.gov |
| TLR Agonist Nano-Immune Therapy for Peritoneal Metastases | NIH | National Cancer Institute | 2024 to 2025 | $948,125 | September 9, 2024 | August 31, 2029 | SERDA, RITA ELENA | reporter.nih.gov |
| Ovarian Epithelial Cancer Progenitor Cell Population | NIH | National Cancer Institute | 2021 to 2022 | $947,095 | May 10, 2018 | April 30, 2024 | XU, XIANGXI MIKE | reporter.nih.gov |
| Glycosylation-dependent mechanisms regulating ovarian tumor cell phenotype | NIH | National Cancer Institute | 2021 to 2023 | $939,559 | May 15, 2014 | March 31, 2025 | BELLIS, SUSAN L | reporter.nih.gov |
| Targeting Stromal Influences on Glutamine Addiction in Ovarian Cancer | NIH | National Cancer Institute | 2021 to 2022 | $934,217 | August 1, 2018 | July 31, 2023 | NAGRATH, DEEPAK | reporter.nih.gov |
| Therapy of PARP inhibitor-associated myeloid neoplasms in ovarian cancer patients | NIH | National Cancer Institute | 2024 to 2025 | $933,644 | May 1, 2024 | April 30, 2029 | KAUFMANN, SCOTT H | reporter.nih.gov |
| GENOMIC ANALYSIS OF INHERITED BREAST AND OVARIAN CANCER | NIH | National Cancer Institute | 2021 | $927,000 | August 10, 2015 | July 31, 2023 | KING, MARY-CLAIRE | reporter.nih.gov |
| RAD51 paralog function in cancer predisposition and genome integrity | NIH | National Institute of Environmental Health Sciences | 2021 to 2022 | $916,740 | March 15, 2021 | June 30, 2022 | BERNSTEIN, KARA A | reporter.nih.gov |
| Vitamin D and Progestins for the Chemoprevention of Fallopian Tube/Ovarian Cancer | NIH | National Cancer Institute | 2021 to 2022 | $908,866 | December 1, 2017 | November 30, 2024 | RODRIGUEZ, GUSTAVO | reporter.nih.gov |
| Methylation and Mutation Assay to Personalize PARP Inhibitor Therapy | NIH | National Cancer Institute | 2021 to 2022 | $900,690 | September 1, 2020 | May 31, 2024 | SWISHER, ELIZABETH MARY | reporter.nih.gov |
| Biomarkers For BRCA1-Deficient Cancers | NIH | National Cancer Institute | 2024 to 2025 | $873,614 | June 1, 2024 | May 31, 2029 | KONG, KIMI Y | reporter.nih.gov |
| Receptor Cross-Talk in Early Metastatic Dissemination | NIH | National Cancer Institute | 2021 to 2022 | $873,374 | July 1, 2006 | January 31, 2024 | STACK, MARY SHARON | reporter.nih.gov |
| Nanoscale Coordination Polymers Co-deliver Chemotherapeutics and siRNAs for Efficacious Treatment of Resistant Ovarian Cancer | NIH | National Cancer Institute | 2021 to 2022 | $839,916 | February 15, 2018 | January 31, 2023 | LIN, WENBIN | reporter.nih.gov |
| A Population Based Study of Ketorolac and Ovarian Cancer Survival | NIH | National Cancer Institute | 2021 to 2023 | $834,487 | February 14, 2020 | January 31, 2025 | COOK, LINDA S | reporter.nih.gov |
| Nano-CRISPR extracellular vesicle sensing system for longitudinal tumor monitoring | NIH | National Cancer Institute | 2024 to 2025 | $831,662 | August 1, 2024 | July 31, 2027 | IM, HYUNGSOON | reporter.nih.gov |
| Facilitated Education and Testing in BRCA Positive Families | NIH | National Cancer Institute | 2021 to 2022 | $827,714 | June 8, 2018 | May 31, 2025 | SCHWARTZ, MARC D | reporter.nih.gov |
| Bio-orthogonal Mid-Infrared Photothermal Imaging of Cancer Metabolism | NIH | National Cancer Institute | 2024 to 2025 | $814,226 | September 1, 2024 | August 31, 2027 | CHENG, JI-XIN | reporter.nih.gov |
| Synthetic lethality based combination approaches to ARID1A mutation in ovarian cancer | NIH | National Cancer Institute | 2022 to 2024 | $811,452 | July 18, 2019 | January 31, 2026 | ZHANG, RUGANG | reporter.nih.gov |
| Proteogenomic studies aimed at understanding ovarian tumor responses to agents targeting the DNA damage response and translating this knowledge into clinical benefit | NIH | National Cancer Institute | 2021 | $811,229 | June 1, 2017 | March 31, 2022 | PAULOVICH, AMANDA G | reporter.nih.gov |
| Evaluation of combination CLK/DYRK (Cirtuvivint) inhibition with PARP inhibition (Olaparib) in BRCA/HRD platinum resistant ovarian cancer | NIH | National Cancer Institute | 2024 to 2025 | $800,888 | September 1, 2024 | August 31, 2029 | CORR, BRADLEY | reporter.nih.gov |
| Targeting base damage repair in BRCA-mutant cancers | NIH | National Cancer Institute | 2024 to 2025 | $800,818 | July 5, 2024 | June 30, 2029 | VERMA, PRIYANKA | reporter.nih.gov |
| Mechanism and Regulation of Homologous Recombination in Genome Maintenance | NIH | National Institute of General Medical Sciences | 2024 to 2025 | $792,500 | July 10, 2024 | April 30, 2029 | NIU, HENGYAO | reporter.nih.gov |
| Role of the microenvironment in ovarian cancer metastasis | NIH | National Cancer Institute | 2022 to 2023 | $781,698 | September 19, 2019 | August 31, 2025 | FUH, KATHERINE CYNTHIA | reporter.nih.gov |
| Decision Support for Multigene Panel Testing and Family Risk Communication among Racially/Ethnically Diverse Young Breast Cancer Survivors | NIH | National Cancer Institute | 2021 to 2025 | $772,525 | July 1, 2021 | June 30, 2027 | JONES, TARSHA | reporter.nih.gov |
| Stem Cell-based Platform for Targeted Enzyme/Prodrug Therapy of Recurrent Ovarian Cancer | NIH | National Cancer Institute | 2021 to 2022 | $771,552 | April 1, 2021 | March 31, 2023 | HATEFI, ARASH | reporter.nih.gov |
| A novel PARP inhibitor PET tracer for breast cancer | NIH | National Cancer Institute | 2021 to 2023 | $747,506 | March 17, 2021 | February 28, 2025 | LIN, LILIE LEMING | reporter.nih.gov |
| Targeting HSP70 in CARM1-expressing epithelial ovarian cancer | NIH | National Cancer Institute | 2022 to 2024 | $747,000 | April 1, 2022 | March 31, 2025 | KARAKASHEV, SERGEY | reporter.nih.gov |
| Therapeutic potential of FANCM for BRCA1-linked cancer | NIH | National Cancer Institute | 2023 to 2025 | $747,000 | April 1, 2022 | August 31, 2026 | PANDAY, ARVIND | reporter.nih.gov |
| Defining the genomic and biologic impact of LINE-1 activity in fallopian tube epithelial cells | NIH | National Cancer Institute | 2025 | $744,575 | May 16, 2025 | April 30, 2030 | RUEDA, BO R. | reporter.nih.gov |
| Identifying new drivers of ovarian cancer from the non-coding genome by converging germline risk variants and somatic mutations | NIH | National Cancer Institute | 2023 to 2025 | $744,548 | January 1, 2021 | June 30, 2026 | PENG, PEI-CHEN | reporter.nih.gov |
| Characterization of the role of super-enhancers in ovarian cancer treatment response | NIH | National Cancer Institute | 2021 to 2023 | $744,490 | August 1, 2019 | August 31, 2024 | LANG, JESSICA DIANE | reporter.nih.gov |
| Culture of tumor versus normal cells | NIH | National Cancer Institute | 2024 to 2025 | $728,280 | January 1, 2024 | December 31, 2028 | INCE, TAN A. | reporter.nih.gov |
| Regulatory Dendritic Cells in Cancer | NIH | National Cancer Institute | 2021 to 2022 | $727,947 | July 1, 2007 | February 28, 2023 | CONEJO-GARCIA, JOSE R | reporter.nih.gov |
| Pre-metastatic Omental Niche Formation in Ovarian Cancer | NIH | National Cancer Institute | 2021 to 2022 | $727,651 | April 1, 2018 | March 31, 2025 | NAORA, HONAMI | reporter.nih.gov |
| Integrative bioinformatics and functional characterization of oncogenic driver aberrations in cancer | NIH | National Cancer Institute | 2021 | $721,618 | August 8, 2018 | July 31, 2023 | MILLS, GORDON B. | reporter.nih.gov |
| Exosomes and platinum-induced peripheral neuropathy | NIH | National Cancer Institute | 2021 to 2022 | $709,918 | July 1, 2018 | June 30, 2024 | ZHANG, ZHENG GANG | reporter.nih.gov |
| Identification of USP13 as a therapeutic target for ovarian cancer | NIH | National Cancer Institute | 2021 to 2022 | $705,011 | February 2, 2018 | January 31, 2023 | LU, XIONGBIN | reporter.nih.gov |
| Quantitative Fluorescence Imaging-Guided Detection and Targeted Therapy Monitoring Platform for Ovarian Cancer Micrometastases | NIH | National Cancer Institute | 2022 to 2025 | $704,419 | December 16, 2022 | March 31, 2027 | SUNAR, ULAS | reporter.nih.gov |
| Countering microtubule stabilization within hair follicles in ovarian cancer chemotherapy | NIH | National Cancer Institute | 2024 to 2025 | $702,262 | April 4, 2024 | March 31, 2029 | XU, XIANGXI MIKE | reporter.nih.gov |
| Development of the MasSpec Pen Technology to Guide Surgical Decisions in the Care for Patients with Ovarian Cancer | NIH | National Cancer Institute | 2025 | $697,317 | August 18, 2025 | July 31, 2030 | SCHIAVINATO EBERLIN, LIVIA | reporter.nih.gov |
| A non-invasive blood test for multi-cancer detection and determination of tissue of origin preceding overt cancer diagnosis | NIH | National Cancer Institute | 2025 | $692,491 | May 1, 2025 | April 30, 2030 | BISSONNETTE, BRUCE MARC | reporter.nih.gov |
| Electronic health record (EHR)-based implementation strategies and decision support for hereditary breast and ovarian cancer (HBOC) genetic testing among multiethnic women (ELISABETH) | NIH | National Cancer Institute | 2025 | $686,993 | March 1, 2025 | February 28, 2027 | CREW, KATHERINE D | reporter.nih.gov |
| Acylcarnitine Metabolism in Ovarian Cancer Chemoresistance | NIH | National Cancer Institute | 2025 | $686,654 | January 1, 2025 | September 1, 2025 | AIRD, KATHERINE MARIE | reporter.nih.gov |
| Impact of microRNA processing on EMT of ovarian cancer cells | NIH | National Cancer Institute | 2021 to 2022 | $678,561 | September 1, 2018 | August 31, 2024 | HUANG, SHUANG | reporter.nih.gov |
| Precision Assessment and Delivery of Cancer Risks in BRCA 1/2 Mutation Cancers | NIH | National Cancer Institute | 2021 | $676,046 | September 18, 2017 | August 31, 2023 | REBBECK, TIMOTHY R | reporter.nih.gov |
| The BRCA Exchange Knowledgebase for Clinical Cancer Genetics | NIH | National Cancer Institute | 2025 | $660,079 | September 1, 2025 | August 31, 2030 | CLINE, MELISSA SUZANNE | reporter.nih.gov |
| Tracking Peripheral T-Cell Repertoire Changes for Preoperative and Early Ovarian Cancer Diagnosis | NIH | National Cancer Institute | 2022 to 2023 | $656,517 | January 1, 2022 | March 31, 2023 | LI, BO | reporter.nih.gov |
| Development and Implementation of a Health e-Librarian with Personalized Recommender (HELPeR) | NIH | National Library of Medicine | 2021 to 2022 | $643,890 | September 5, 2019 | January 31, 2025 | LEE, YOUNG JI | reporter.nih.gov |
| Pilot in vivo trial with T-cell-based delivery of immunostimulatory proteins | NIH | National Cancer Institute | 2024 to 2025 | $639,527 | June 1, 2024 | November 30, 2026 | LIU, XIAOHE | reporter.nih.gov |
| Engineering high performing microfluidic system for rapid non-invasive isolation and expansion of circulating tumor-reactive lymphocytes | NIH | National Cancer Institute | 2025 | $637,371 | January 1, 2025 | December 31, 2029 | KELLEY, SHANA O | reporter.nih.gov |
| Synthetic lethality based combination approaches to ARID1A mutation in ovarian cancer | NIH | National Cancer Institute | 2021 to 2022 | $637,231 | July 18, 2019 | January 31, 2023 | ZHANG, RUGANG | reporter.nih.gov |
| Summer Undergraduate Research Fellowship in the Molecular Biology and Genomics of Human Cancer | NIH | National Cancer Institute | 2021 to 2025 | $636,425 | July 1, 2019 | June 30, 2030 | CHUANG, JEFFREY HSU-MIN | reporter.nih.gov |
| Development of Personalized Intact Proteome Map for Ovarian Cancer Patients Using Ultrasensitive Multiplexed Top-down Proteomics | NIH | National Cancer Institute | 2025 | $631,621 | August 13, 2025 | July 31, 2028 | WU, SI | reporter.nih.gov |
| Isoquercetin as a PDI inhibitor: dose-optimization and patient phenotyping | NIH | National Center for Complementary & Integrative Health | 2025 | $631,382 | April 15, 2025 | January 31, 2030 | ZWICKER, JEFFREY | reporter.nih.gov |
| Comparative Effectiveness of Interventions to Increase Guideline-based Genetic Counseling in Ethnically and Geographically Diverse Cancer Survivors | NIH | National Cancer Institute | 2021 | $618,436 | December 22, 2016 | November 30, 2023 | KINNEY, ANITA Y. | reporter.nih.gov |
| Nanotechnology-based personalized treatment of metastatic ovarian cancer | NIH | National Cancer Institute | 2022 | $617,999 | June 3, 2022 | May 31, 2023 | MINKO, TAMARA | reporter.nih.gov |
| A novel multimodal ECM analysis platform for tumor characterization combining morphological and spectrochemical tissue imaging approaches. | NIH | National Cancer Institute | 2023 to 2025 | $614,787 | August 1, 2023 | July 31, 2026 | CAMPAGNOLA, PAUL J | reporter.nih.gov |
| Characterizing non-coding somatic and germline variant interactions in ovarian cancer | NIH | National Cancer Institute | 2024 | $614,121 | June 1, 2020 | May 31, 2025 | GAYTHER, SIMON ANDREW | reporter.nih.gov |
| Immune Impact on Cancer Chemoresistance | NIH | National Cancer Institute | 2021 | $613,838 | January 1, 2017 | December 31, 2021 | ZOU, WEIPING | reporter.nih.gov |
| Functional Effects of Ovarian Cancer Risk Variants | NIH | National Cancer Institute | 2021 | $612,989 | January 1, 2017 | December 31, 2022 | GAYTHER, SIMON ANDREW | reporter.nih.gov |
| Elevated collagen I and fibronectin in the ovarian cancer pre-metastatic niche | NIH | National Cancer Institute | 2025 | $612,288 | December 11, 2024 | November 30, 2029 | KREEGER, PAMELA K | reporter.nih.gov |
| Unraveling the Role of MMP3 in the Cisplatin Resistance of Ovarian Cancer | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $605,902 | May 11, 2022 | April 30, 2027 | VIVAS-MEJIA, PABLO ELIAS | reporter.nih.gov |
| Common biology underlying pleiotropic breast, prostate and ovarian cancer risk loci | NIH | National Cancer Institute | 2024 | $599,202 | September 1, 2022 | August 31, 2027 | GAYTHER, SIMON ANDREW | reporter.nih.gov |
| Metasurface enhanced and machine learning aided spectrochemical liquid biopsy | NIH | National Institute of Biomedical Imaging and Bioengineering | 2023 to 2025 | $595,360 | March 1, 2023 | February 28, 2026 | YESILKOY, FILIZ | reporter.nih.gov |
| Eliminating variants of uncertain significance in BRCA1, BRCA2 and beyond | NIH | National Cancer Institute | 2021 | $594,699 | September 1, 2019 | August 31, 2023 | CLINE, MELISSA SUZANNE | reporter.nih.gov |
| The role of fallopian tube microbiome in ovarian carcinogenesis | NIH | National Cancer Institute | 2021 to 2023 | $588,636 | March 1, 2023 | February 29, 2024 | YU, BO | reporter.nih.gov |
| Elucidating spatiotemporal dynamics of nascent extracellular matrix in response to platinum treatment in ovarian cancer | NIH | National Cancer Institute | 2025 | $584,081 | May 12, 2025 | April 30, 2030 | DE LA PUENTE, PILAR | reporter.nih.gov |
| Programa de ARBOLES Familiares: Assessing Risk of Breast Cancer through Outreach to Latinas with Education and Support | NIH | National Cancer Institute | 2021 to 2022 | $580,282 | August 1, 2017 | November 30, 2023 | GRAVES, KRISTI D. | reporter.nih.gov |
| Engineering T cells to overcome inhibitory receptor signals that limit the efficacy of adoptive cell therapy against ovarian cancer | NIH | National Cancer Institute | 2023 to 2025 | $565,660 | June 5, 2023 | May 31, 2026 | ANDERSON, KRISTIN GAIL | reporter.nih.gov |
| Attacking aggressive p53 mutants in gynecologic cancer | NIH | National Cancer Institute | 2022 to 2024 | $560,520 | August 1, 2022 | July 31, 2025 | THIEL, KRISTINA W | reporter.nih.gov |
| Mechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancer | NIH | National Cancer Institute | 2021 to 2022 | $553,886 | December 1, 2015 | January 31, 2023 | ZHANG, RUGANG | reporter.nih.gov |
| The roles of anti-apoptotic proteins BCL-XL and MCL1 in mediating survival of high-grade serous ovarian cancer following drug-induced DNA damage | NIH | National Cancer Institute | 2021 to 2023 | $553,020 | July 1, 2019 | June 30, 2025 | STOVER, ELIZABETH HARMON | reporter.nih.gov |
| KAT6A as a novel druggable target for cancer treatment: mechanisms and therapeutic implications in KAT6A-dependent tumors | NIH | National Cancer Institute | 2025 | $552,763 | January 1, 2025 | December 31, 2029 | ZHANG, LIN | reporter.nih.gov |
| Characterizing Molecular Subtypes of Ovarian Cancer in African-American Women | NIH | National Cancer Institute | 2021 | $550,732 | October 1, 2016 | December 31, 2023 | DOHERTY, JENNIFER A. | reporter.nih.gov |
| Program control of CD8+ T cell response to tumors and tumor memory | NIH | National Cancer Institute | 2025 | $549,460 | August 13, 2025 | April 30, 2030 | AVRAM, DORINA | reporter.nih.gov |
| Retroviral Replicating Vector-mediated Gene Therapy for Ovarian Cancer | NIH | National Cancer Institute | 2022 | $519,704 | August 1, 2017 | July 31, 2023 | KASAHARA, NORIYUKI | reporter.nih.gov |
| PQ#12; Targeting Nampt-mediated NAD+ metabolism in chemobrain | NIH | National Cancer Institute | 2021 | $510,674 | August 8, 2019 | July 31, 2022 | JANG, MI-HYEON | reporter.nih.gov |
| Strategies for discerning chemotherapy response and resistance in ovarian cancer | NIH | National Cancer Institute | 2022 | $510,364 | September 15, 2022 | August 31, 2025 | WEI, WEI | reporter.nih.gov |
| Preclinical Development of the Novel Inhibitor of Apoptosis Proteins S2/IAPinh for Cancer Therapy | NIH | National Cancer Institute | 2024 to 2025 | $505,894 | December 29, 2022 | November 30, 2027 | HAWKINS, WILLIAM G | reporter.nih.gov |
| Multi-Modal Imaging of Psychostimulant Effects on Executive Function Post-RRSO | NIH | National Cancer Institute | 2021 | $503,265 | April 21, 2017 | March 31, 2023 | EPPERSON, C. NEILL | reporter.nih.gov |
| Targeted therapeutics for ovarian cancer and its microenvironment - treatment and theoretical modeling | NIH | National Cancer Institute | 2021 | $500,198 | June 1, 2017 | May 31, 2023 | LOPEZ-BERESTEIN, GABRIEL | reporter.nih.gov |
| Leica STELLARIS Confocal to Power Women's Health Research | NIH | Office of the Director, National Institutes of Health | 2021 | $496,935 | September 1, 2021 | August 31, 2022 | YANOWITZ, JUDITH L | reporter.nih.gov |
| Obesity Increases Breast Cancer Penetrance in BRCA Mutation Carriers: A Role for Local and Systemic Factors | NIH | National Cancer Institute | 2021 | $495,715 | April 1, 2017 | March 31, 2023 | BROWN, KRISTY A. | reporter.nih.gov |
| Unraveling the Impact of Extracellular Vesicle-Loaded FXR1 mRNA on Re-educating Cancer Microenvironment | NIH | National Cancer Institute | 2025 | $494,160 | September 11, 2025 | August 31, 2030 | CHALUVALLY-RAGHAVAN, PRADEEP | reporter.nih.gov |
| Regulation of mRNA homeostasis by PD-L1 | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $492,000 | May 15, 2023 | April 30, 2027 | VANCUROVA, IVANA | reporter.nih.gov |
| Averting recurrent and resistant ovarian tumors | NIH | National Cancer Institute | 2021 | $490,751 | December 19, 2016 | May 31, 2023 | WANG, QIEN | reporter.nih.gov |
| Platinum-Gold Compounds as Potential Chemo- and Targeted Agents for Ovarian Cancer | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $485,701 | August 4, 2023 | June 30, 2027 | CONTEL, MARIA | reporter.nih.gov |
| Proteomic, Genomic, and Longitudinal Pathways to Ovarian Cancer Biomarker Discovery | NIH | National Cancer Institute | 2021 | $483,194 | April 1, 2021 | March 31, 2024 | SKATES, STEVEN J | reporter.nih.gov |
| Personalized cancer models to discover and develop new therapeutic targets. | NIH | National Cancer Institute | 2021 | $470,312 | September 14, 2017 | March 31, 2022 | KEMP, CHRISTOPHER J | reporter.nih.gov |
| Cancer cell-intrinsic mitochondrial stress responses influence protective immunity | NIH | National Cancer Institute | 2025 | $468,373 | December 1, 2024 | November 30, 2029 | PAYNE, KYLE KRISTOPHER | reporter.nih.gov |
| Molecularly-Targeted Ultrasound in Ovarian Cancer | NIH | National Cancer Institute | 2021 | $467,885 | May 1, 2017 | April 30, 2023 | EL KAFFAS, AHMED | reporter.nih.gov |
| Chemotherapy induced MASP activation and ovarian cancer metastasis | NIH | National Cancer Institute | 2025 | $465,020 | February 1, 2025 | January 31, 2030 | ANTALIS, TONI M | reporter.nih.gov |
| Development of Novel Metal-Based Supramolecular Therapeutics for Ovarian Cancer | NIH | National Cancer Institute | 2021 | $454,646 | January 15, 2021 | March 31, 2024 | ZHENG, YAORONG | reporter.nih.gov |
| Targeting MUC16 transactivation for ovarian cancer treatment | NIH | National Cancer Institute | 2022 to 2023 | $447,603 | January 1, 2022 | December 31, 2025 | WANG, EDWARD WENGE | reporter.nih.gov |
| Targeting sfRon-S6K1 signaling and mitotic kinesin Eg5 in ovarian cancer: a novel synergistic treatment strategy | NIH | National Cancer Institute | 2021 to 2022 | $445,369 | August 2, 2021 | January 31, 2024 | BIENIASZ, MAGDALENA | reporter.nih.gov |
| Targeting RANKL for the treatment of muscle and bone defects in cachexia | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 | $441,832 | July 12, 2021 | May 31, 2026 | BONETTO, ANDREA | reporter.nih.gov |
| Tumor-targeted nanoparticle-based delivery system for imaging and treatment of cancer | NIH | National Cancer Institute | 2021 | $441,713 | April 21, 2017 | September 30, 2024 | MINKO, TAMARA | reporter.nih.gov |
| Functional contributions of glycogen metabolism to ovarian cancer metastasis | NIH | National Cancer Institute | 2021 | $440,454 | June 1, 2020 | May 31, 2022 | LENGYEL, ERNST | reporter.nih.gov |
| An engineered prodrug for inhibition of cancer growth and metastasis | NIH | National Cancer Institute | 2025 | $435,773 | January 3, 2025 | December 31, 2029 | ANTALIS, TONI M | reporter.nih.gov |
| Role of the microenvironment in ovarian cancer metastasis | NIH | National Cancer Institute | 2021 | $433,904 | September 19, 2019 | June 30, 2022 | FUH, KATHERINE CYNTHIA | reporter.nih.gov |
| Development of bifunctional CDK2 inhibitors for treatment of CCNE1-driven cancers | NIH | National Cancer Institute | 2024 to 2025 | $433,255 | April 1, 2024 | March 31, 2026 | SCHONBRUNN, ERNST | reporter.nih.gov |
| Tumor Metabolic Profiling by Multiplexed Single-Cell Lipid and mRNA Imaging | NIH | National Cancer Institute | 2024 to 2025 | $433,092 | March 5, 2024 | February 28, 2027 | HEILSHORN, SARAH C | reporter.nih.gov |
| Role of microbiota in therapy to ovarian cancer | NIH | National Cancer Institute | 2021 | $426,139 | April 10, 2017 | March 31, 2023 | RANDALL, TROY D | reporter.nih.gov |
| Macrophage-based ovarian cancer immunotherapy | NIH | National Cancer Institute | 2021 | $424,055 | March 10, 2017 | February 28, 2023 | YULL, FIONA E | reporter.nih.gov |
| Mitigate cisplatin induced acute kidney injury through preservation of vasculature and proximal tubule | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 | $424,049 | April 1, 2021 | March 31, 2022 | PAN, HUA | reporter.nih.gov |
| Role of extracellular matrix remodeling on high-grade serous ovarian carcinoma immune evasion | NIH | National Cancer Institute | 2022 to 2023 | $422,948 | April 1, 2022 | March 31, 2025 | DE LA PUENTE, PILAR | reporter.nih.gov |
| RESISTANCE AND RESPONSE SIGNALING TO PARP1 INHIBITORS IN OVARIAN CANCER | NIH | National Cancer Institute | 2021 to 2022 | $419,636 | February 1, 2021 | January 31, 2024 | MONTEIRO, ALVARO N | reporter.nih.gov |
| Machine Learning-enabled Classification of Extracellular Vesicles Using Nanoplasmonic Microfluidics | NIH | National Institute of Biomedical Imaging and Bioengineering | 2024 to 2025 | $419,284 | September 12, 2024 | August 31, 2027 | HISEY, COLIN LEE | reporter.nih.gov |
| Advanced Development of Patient Ascites Therapeutic Response Biosensors | NIH | National Cancer Institute | 2025 | $419,133 | March 1, 2025 | February 29, 2028 | BOEHM, JESSE SAMUEL | reporter.nih.gov |
| Breast, Colorectal, and Ovary Cancer Clinical Validation Center | NIH | National Cancer Institute | 2021 | $418,953 | August 16, 2010 | March 31, 2022 | LI, CHRISTOPHER I | reporter.nih.gov |
| Role of OCIAD1 in RIG-I-mediated STAT1 signaling pathway | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $418,000 | January 24, 2022 | December 31, 2024 | LI, SHITAO | reporter.nih.gov |
| High-Resolution Dynamic Imaging of Ovarian Cancer Metastasis Post Chemotherapy | NIH | National Cancer Institute | 2021 to 2022 | $417,157 | December 8, 2020 | November 30, 2023 | IWANICKI, MARCIN | reporter.nih.gov |
| Contribution of Epigenome to PRKCI-Driven High-Grade Serous Ovarian Cancer | NIH | National Cancer Institute | 2021 | $416,543 | May 1, 2021 | April 30, 2023 | RAI, KUNAL | reporter.nih.gov |
| Targeting MDM4 in Rare Refractory Ovarian Cancer Sub-Types | NIH | National Cancer Institute | 2024 to 2025 | $416,543 | December 20, 2023 | November 30, 2026 | SIDDIK, ZAHID H | reporter.nih.gov |
| Identifying the Drivers and Targeting Chemo Resistance in Ovarian Cancer | NIH | National Cancer Institute | 2021 | $413,874 | March 1, 2017 | February 28, 2022 | ADLI, MAZHAR | reporter.nih.gov |
| CCNE1 is synthetically lethal with drug induced nuclear Cathepsin L (nCTSL) | NIH | National Cancer Institute | 2025 | $412,429 | August 1, 2025 | July 31, 2027 | SHRIDHAR, VIJI | reporter.nih.gov |
| Explore piRNAs as a novel group of biomarkers for ovarian cancer early detection | NIH | National Cancer Institute | 2024 | $411,876 | May 1, 2024 | April 30, 2026 | ZHU, YONG | reporter.nih.gov |
| Molecular Mechanisms regulating Primordial Follicle Formation | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 to 2025 | $410,500 | July 15, 2024 | June 30, 2027 | PEPLING, MELISSA E | reporter.nih.gov |
| Hyperthermic Intraperitoneal Chemotherapy Mechanisms in Epithelial Ovarian Cancer | NIH | National Cancer Institute | 2021 to 2022 | $410,209 | June 1, 2021 | May 31, 2023 | REIZES, OFER | reporter.nih.gov |
| Multi-omic Predictive Markers for Ovarian Cancer Therapy Response and Outcomes | NIH | National Cancer Institute | 2022 to 2023 | $407,750 | August 8, 2022 | July 31, 2025 | MODUGNO, FRANCESMARY | reporter.nih.gov |
| Development of a Therapeutic Monoclonal Antibody Against EGFL6, a Mediator of Tumor Growth and Metastasis | NIH | National Cancer Institute | 2021 | $405,552 | April 20, 2021 | March 31, 2023 | ALLEN, THADDEUS DAVID | reporter.nih.gov |
| Boosting anti-tumor immunity in the omentum for metastasis prevention | NIH | National Cancer Institute | 2023 to 2024 | $405,184 | May 2, 2023 | April 30, 2026 | NAORA, HONAMI | reporter.nih.gov |
| PG545 synergizes with PARP inhibitors in ovarian cancer to disrupt DNA repair through modulation of DEK-RAD51 axis | NIH | National Cancer Institute | 2022 to 2023 | $404,369 | February 1, 2022 | January 31, 2025 | SHRIDHAR, VIJI | reporter.nih.gov |
| Development and Pilot Testing of a Collaborative Agenda-Setting Intervention to Promote Patient-Centered Communication in Ovarian Cancer Care | NIH | National Institute of Nursing Research | 2023 to 2025 | $401,474 | May 15, 2023 | April 30, 2027 | POZZAR, RACHEL | reporter.nih.gov |
| Development of small molecule RPN13 inhibitors for Treatment of Glioblastoma | NIH | National Cancer Institute | 2022 | $400,000 | September 1, 2022 | August 31, 2024 | ANCHOORI, RAVI KUMAR | reporter.nih.gov |
| Development of a DISE-inducing, short RNA therapeutic to treat ovarian cancer | NIH | National Cancer Institute | 2025 | $400,000 | June 9, 2025 | May 31, 2027 | SCHICKEL, ROBERT | reporter.nih.gov |
| Nanoparticle formulation of Mediator kinase inhibitor for the treatment of peritoneal ovarian cancer | NIH | National Cancer Institute | 2025 | $400,000 | December 13, 2024 | November 30, 2025 | CHEN, MENGQIAN | reporter.nih.gov |
| Development of a biomarker panel for screening and early detection of gynecological cancers | NIH | National Cancer Institute | 2021 | $399,972 | September 1, 2021 | August 31, 2023 | MARTIGNETTI, JOHN A | reporter.nih.gov |
| Novel STAT3 inhibitor for overcoming chemoresistant ovarian cancer . | NIH | National Cancer Institute | 2022 | $399,869 | September 15, 2022 | August 31, 2024 | OZES, ALI RAYET | reporter.nih.gov |
| A novel ctDNA analysis solution for the next-generation of liquid biopsy assays | NIH | National Cancer Institute | 2025 | $399,816 | September 1, 2025 | August 31, 2026 | MIR, KALIM ULLAH | reporter.nih.gov |
| Identifying new drivers of ovarian cancer from the non-coding genome by converging germline risk variants and somatic mutations | NIH | National Cancer Institute | 2021 to 2022 | $399,660 | January 1, 2021 | June 30, 2023 | PENG, PEI-CHEN | reporter.nih.gov |
| Development of Lasso Peptides as Potent Endothelin Receptor B Antagonists for Immuno-oncology | NIH | National Cancer Institute | 2021 | $399,609 | July 1, 2021 | June 30, 2023 | BURK, MARK J | reporter.nih.gov |
| Multi-Modality Optical Molecular Imaging System for Preclinical Cancer Models | NIH | National Cancer Institute | 2024 | $399,491 | September 1, 2024 | February 28, 2025 | MOY, AUSTIN | reporter.nih.gov |
| A novel targeted antibody therapeutic to treat ovarian cancer | NIH | National Cancer Institute | 2024 | $399,478 | June 1, 2024 | May 31, 2026 | LAUS, REINER | reporter.nih.gov |
| Outpatient Screening for Early-Stage High-Grade Serous Ovarian Cancer in Higher Risk Women | NIH | National Cancer Institute | 2021 | $399,331 | September 2, 2021 | August 31, 2024 | BLACK, JOHN | reporter.nih.gov |
| Targeting and Imaging Ovarian Cancer with Junction Opener Conjugated-Lipid Iron Oxide Nanoparticles (JOC-LIONs) | NIH | National Cancer Institute | 2021 | $399,285 | September 1, 2021 | August 31, 2023 | KHANDHAR, AMIT PRAFUL | reporter.nih.gov |
| An allogeneic gamma/delta armored Dual-Targeting CAR with Split Costimulatory Domains to Target Epithelial Ovarian Carcinoma | NIH | National Cancer Institute | 2024 | $399,256 | September 13, 2024 | August 31, 2025 | HICKENLOOPER, SAMUEL | reporter.nih.gov |
| Therapeutic potential of targeting DNA repair deficiency in TSC | NIH | National Cancer Institute | 2021 to 2022 | $398,743 | July 1, 2021 | June 30, 2024 | MACKEIGAN, JEFFREY PAUL | reporter.nih.gov |
| Development of Novel CD180-Based Cancer Immunotherapeutics | NIH | National Cancer Institute | 2022 | $398,040 | June 1, 2022 | May 31, 2024 | CLARK, EDWARD A | reporter.nih.gov |
| Lectikines for Immunotherapy against Ovarian Cancer | NIH | National Cancer Institute | 2024 to 2025 | $397,465 | February 1, 2024 | January 31, 2027 | MATOBA, NOBUYUKI | reporter.nih.gov |
| Mechanisms of Th17-DC immunotherapy for ovarian cancer | NIH | National Cancer Institute | 2024 to 2025 | $393,402 | March 7, 2024 | February 28, 2027 | CANNON, MARTIN J | reporter.nih.gov |
| A novel polymer-metal nanocomplex for ovarian cancer treatment | NIH | National Cancer Institute | 2021 | $392,803 | January 1, 2021 | December 31, 2022 | XU, PEISHENG | reporter.nih.gov |
| Biodegradable nanocarriers and antibodies as targeting delivery vehicles for cancer metallodrugs | NIH | National Institute of General Medical Sciences | 2021 | $392,500 | June 1, 2018 | July 31, 2023 | CONTEL, MARIA | reporter.nih.gov |
| Repurposing Auranofin As a Novel Notch Pathway Inhibitor for Combinational Ovarian Cancer Therapy | NIH | National Cancer Institute | 2024 to 2025 | $392,115 | January 1, 2024 | November 30, 2026 | FAN, HUA-YING | reporter.nih.gov |
| Targeting Atg5 in platinum-resistant ovarian cancer | NIH | National Cancer Institute | 2021 to 2022 | $391,653 | January 1, 2021 | December 31, 2023 | WU, GEN SHENG | reporter.nih.gov |
| Antibody-based prertargeted alpha particle therapy for ovarian cancer | NIH | National Cancer Institute | 2024 | $391,553 | June 5, 2024 | November 30, 2025 | SCHULTZ, MICHAEL KING | reporter.nih.gov |
| Development of a Theranostic Nanomedicine Construct for Ovarian Cancer | NIH | National Cancer Institute | 2021 | $390,858 | April 15, 2021 | March 31, 2023 | GARRISON, JERED C | reporter.nih.gov |
| Optimizing Radiosynthetic Yield of [18F]FTT For Wide-Spread Distribution | NIH | National Cancer Institute | 2021 | $390,058 | April 1, 2021 | March 31, 2022 | SCHWARZ, SALLY WAGNER | reporter.nih.gov |
| Biologic rationale of fallopian tube removal to prevent uterine serous carcinoma | NIH | National Cancer Institute | 2025 | $388,256 | September 1, 2025 | August 31, 2027 | DELANEY, JOE R | reporter.nih.gov |
| Preclinical development and validation of targeted mass spectrometry assays for serous ovarian cancer diagnosis | NIH | National Cancer Institute | 2025 | $386,700 | July 7, 2025 | June 30, 2027 | THOMAS, STEFANI | reporter.nih.gov |
| Targeted proteomics of MUC16 to enable early detection of ovarian cancer recurrence | NIH | National Cancer Institute | 2022 to 2023 | $386,339 | January 1, 2022 | June 30, 2025 | WHELAN, REBECCA JEAN | reporter.nih.gov |
| Investigating 53BP1 'dephosphorylation' as a critical determinant of PARP | NIH | National Cancer Institute | 2021 | $384,923 | March 15, 2017 | February 28, 2023 | CHOWDHURY, DIPANJAN | reporter.nih.gov |
| Targeting RHNO1 in Ovarian Cancer | NIH | National Cancer Institute | 2023 to 2024 | $383,923 | April 1, 2023 | March 31, 2026 | KARPF, ADAM R. | reporter.nih.gov |
| Adipose tissue immunometabolism in ovarian cancer progression and chemoresistance | NIH | National Cancer Institute | 2022 to 2025 | $382,798 | September 1, 2021 | May 31, 2026 | YEE, SAMANTHA | reporter.nih.gov |
| Chronic Stress and Vaginal Fluid Metabolomics Signatures in Ovarian Cancer | NIH | National Cancer Institute | 2024 to 2025 | $378,381 | September 1, 2024 | August 31, 2027 | OSAZUWA-PETERS, OYOMOARE L | reporter.nih.gov |
| Sensitizing High Grade Serous Cancers to Immunotherapy through the Induction of DNA Damage | NIH | National Cancer Institute | 2021 to 2022 | $377,818 | July 1, 2020 | August 31, 2022 | MCLEAN, KAREN | reporter.nih.gov |
| Experimental Therapeutics by targeting Spleen Tyrosine Kinase | NIH | National Cancer Institute | 2021 | $375,163 | March 1, 2017 | February 28, 2023 | SHIH, IE-MING | reporter.nih.gov |
| Reducing Off-Target Accumulation of Chemotherapeutic Nanomedicines | NIH | National Cancer Institute | 2025 | $375,134 | March 1, 2025 | February 28, 2030 | ANCHORDOQUY, THOMAS | reporter.nih.gov |
| Bioreactor for Manufacturing Chemotactically Competent Immune Cell Therapies | NIH | National Cancer Institute | 2024 | $375,016 | May 1, 2024 | April 30, 2025 | LIU, XIAOHE | reporter.nih.gov |
| Analysis of BRCA1 recombination functions | NIH | National Cancer Institute | 2021 | $374,063 | May 1, 2002 | July 31, 2022 | SCULLY, RALPH | reporter.nih.gov |
| Development of a Novel Nectin Targeting Antibody-drug Conjugate for Ovarian Cancer Therapy | NIH | National Cancer Institute | 2024 | $371,070 | September 19, 2024 | August 31, 2025 | DELGADO, OLIVER | reporter.nih.gov |
| CAR T platform to treat solid tumors | NIH | National Cancer Institute | 2022 | $368,052 | August 1, 2022 | December 31, 2023 | MURAD, JOANA M | reporter.nih.gov |
| Psychosocial Stress, Vaginal Microbiome, and Ovarian Cancer: An Integrative Framework | NIH | National Cancer Institute | 2023 to 2025 | $367,632 | May 24, 2023 | April 30, 2028 | DEVEAUX, APRIL | reporter.nih.gov |
| Cell Cycle Blockade and Therapeutic Sensitization | NIH | National Cancer Institute | 2021 | $366,000 | July 6, 2017 | May 31, 2023 | SIDDIK, ZAHID H | reporter.nih.gov |
| Preclinical development of the novel inhibitor of apoptosis proteins S2/IAPinh for cancer therapy | NIH | National Cancer Institute | 2023 to 2024 | $359,498 | December 29, 2022 | March 16, 2024 | SPITZER, DIRK M. | reporter.nih.gov |
| Role of MAST1 kinase in cisplatin resistant cancers | NIH | National Cancer Institute | 2021 | $356,850 | June 15, 2017 | May 31, 2023 | KANG, SUMIN | reporter.nih.gov |
| Preclinical Efficacy of Allogeneic and Human Silicified Cancer Vaccines | NIH | National Cancer Institute | 2024 | $356,469 | July 1, 2024 | June 30, 2026 | SERDA, RITA ELENA | reporter.nih.gov |
| TUMOR-DERIVED EXTRACELLULAR VESICLES FOR DIAGNOSIS OF EARLY-STAGE OVARIAN CANCER | NIH | National Cancer Institute | 2025 | $354,828 | September 15, 2025 | September 14, 2026 | reporter.nih.gov | |
| NOVEL THERANOSTIC RADIOLIGANDS TARGETING DISEASE-SPECIFIC EXTRACELLULAR MATRIX COMPONENTS SPECIFIC TO TUMOR AND METASTATIC LESIONS IN PATIENTS SUFFERING FROM HEREDITARY BREAST AND OVARIAN CANCER (HBOC | NIH | National Cancer Institute | 2025 | $354,456 | September 15, 2025 | September 14, 2026 | reporter.nih.gov | |
| Protease activated receptor-2 (PAR-2) signaling and metastatic ovarian cancer | NIH | National Cancer Institute | 2021 | $353,419 | August 1, 2017 | July 31, 2022 | ANTALIS, TONI M | reporter.nih.gov |
| Nicotinamide N-Methyltransferase (NNMT) as a master regulator of cancer stroma | NIH | National Cancer Institute | 2021 | $351,637 | June 15, 2017 | May 31, 2022 | LENGYEL, ERNST | reporter.nih.gov |
| A novel platform for targeted radiopharmaceuticals for imaging and therapy of ovarian cancer | NIH | National Cancer Institute | 2024 | $349,808 | September 1, 2024 | August 31, 2025 | LAPI, SUZANNE ELIZABETH | reporter.nih.gov |
| Promoting gynecologic cancer patients with frailty to achieve functional recovery cohort study (PROOF Cohort Study) | NIH | National Institute on Aging | 2024 | $349,561 | September 1, 2024 | August 31, 2026 | CHAM, STEPHANIE | reporter.nih.gov |
| A genotype-phenotype study of tumors from patients with inherited mutations in DNA repair genes | NIH | National Cancer Institute | 2021 to 2022 | $347,938 | March 1, 2018 | February 28, 2023 | MAXWELL, KARA N | reporter.nih.gov |
| SBIR Diagnostic Method to Identify approved drugs as treatment options in individuals with rare cancer | NIH | National Cancer Institute | 2023 | $340,334 | February 28, 2023 | February 27, 2024 | PEDERSEN, GITTE | reporter.nih.gov |
| Quantitative Fluorescence Imaging-Guided Detection and Targeted Therapy Monitoring Platform for Ovarian Cancer Micrometastases | NIH | National Cancer Institute | 2021 | $336,645 | August 1, 2020 | April 30, 2025 | SUNAR, ULAS | reporter.nih.gov |
| Genome-wide Sequencing to Identify the Genes Responsible for Enchondromatoses and Related Malignant Tumors | NIH | National Cancer Institute | 2021 to 2022 | $327,500 | July 8, 2021 | June 30, 2024 | SOBREIRA, NARA | reporter.nih.gov |
| T-cell engaging bispecific antibodies designed for proteolytic activation in the tumor microenvironment | NIH | National Cancer Institute | 2021 to 2022 | $326,488 | July 20, 2021 | March 10, 2023 | RADER, CHRISTOPH | reporter.nih.gov |
| Protein-nanoparticle interaction to study multicellular crosstalk within ovarian tumor microenviroment | NIH | National Cancer Institute | 2025 | $326,103 | January 16, 2025 | December 31, 2029 | MUKHERJEE, PRIYABRATA | reporter.nih.gov |
| A PILOT STUDY OF PREHABILITATION DURING THE NEOADJUVANT WINDOW OF OPPORTUNITY IN OLDER WOMEN WITH OVARIAN CANCER (FIT4SURGERY) | NIH | National Institute on Aging | 2021 to 2022 | $320,000 | September 1, 2021 | May 31, 2024 | BARBER, EMMA | reporter.nih.gov |
| Control of Commitment Steps in Mammalian Homologous Recombination | NIH | National Cancer Institute | 2021 | $319,991 | February 1, 2021 | April 30, 2021 | BUNTING, SAMUEL | reporter.nih.gov |
| Development of in vitro diagnostic multivariate index assay using liquid-based cervical cytology specimen and/or serum/plasma biomarkers for the detection of early stage or low-volume ovarian cancer | NIH | National Cancer Institute | 2021 | $309,067 | April 1, 2016 | March 31, 2023 | ZHANG, ZHEN | reporter.nih.gov |
| Examining the Role of RNF168 Activity in BRCA1 Mutant Cancers | NIH | National Cancer Institute | 2023 to 2024 | $306,748 | September 1, 2023 | August 31, 2026 | KRAIS, JOHN | reporter.nih.gov |
| Spatial and Bayesian modeling methods for assessment of the tumor immune microenvironment and survival of women with ovarian cancer | NIH | National Cancer Institute | 2023 | $304,046 | May 1, 2023 | December 1, 2023 | FRIDLEY, BROOKE L | reporter.nih.gov |
| Mechanisms of heterochromatin replication | NIH | National Institute of General Medical Sciences | 2021 | $301,059 | January 1, 2018 | December 31, 2022 | SMOLKA, MARCUS | reporter.nih.gov |
| Radiomic biomarkers for clinical decision support that predict patient outcomes in serous ovarian carcinoma | NIH | National Cancer Institute | 2024 | $299,995 | September 13, 2024 | August 31, 2025 | PERES, LAUREN COLE | reporter.nih.gov |
| Novel Drug for Cancer Immunotherapy that Targets Phosphatidylserine | NIH | National Cancer Institute | 2021 | $293,178 | March 11, 2021 | September 30, 2022 | BANKERT, RICHARD B | reporter.nih.gov |
| Identifying factors associated with ovarian cancer recurrence using a population-based approach | NIH | National Cancer Institute | 2023 to 2024 | $279,172 | February 1, 2023 | August 31, 2024 | COLLIN, LINDSAY JANE | reporter.nih.gov |
| Inhibiting beta-adrenergic and COX-2 signaling during the perioperative period to reduce ovarian cancer progression | NIH | National Cancer Institute | 2024 to 2025 | $274,006 | September 1, 2024 | August 31, 2027 | BEN-ELIYAHU, SHAMGAR | reporter.nih.gov |
| Targeting EZH2 in CARM1-expressing epithelial ovarian cancer | NIH | National Cancer Institute | 2021 | $263,785 | August 18, 2012 | January 31, 2023 | ZHANG, RUGANG | reporter.nih.gov |
| Engineering viral nanoparticles for TLR agonist-based multi-functional cancer immunotherapies | NIH | National Cancer Institute | 2024 to 2025 | $260,700 | May 1, 2024 | June 30, 2025 | ZHAO, ZHONGCHAO | reporter.nih.gov |
| Generating rapid antitumor immunity with lymphocyte-reprogramming nanocarriers | NIH | National Cancer Institute | 2021 | $253,224 | July 1, 2017 | March 31, 2022 | STEPHAN, MATTHIAS | reporter.nih.gov |
| Genetic testing in young women for cancer prevention | NIH | National Cancer Institute | 2021 to 2022 | $252,660 | July 5, 2018 | October 31, 2023 | GUO, FANGJIAN | reporter.nih.gov |
| Single cell chromatin profiling to study epigenetic alterations of ovarian tumors | NIH | National Cancer Institute | 2022 to 2023 | $249,362 | September 1, 2022 | August 31, 2025 | GOPALAN, SNEHA | reporter.nih.gov |
| Engineering viral nanoparticles for TLR agonist-based multi-functional cancer immunotherapies | NIH | National Cancer Institute | 2025 | $249,000 | May 1, 2024 | August 31, 2028 | ZHAO, ZHONGCHAO | reporter.nih.gov |
| Identifying factors associated with ovarian cancer recurrence using a population-based approach | NIH | National Cancer Institute | 2025 | $248,858 | February 1, 2023 | December 31, 2027 | COLLIN, LINDSAY JANE | reporter.nih.gov |
| Genetic testing, treatment use, and mortality after diagnosis of breast and ovarian cancer: The Georgia-California GeneLINK Initiative | NIH | National Cancer Institute | 2021 | $247,753 | March 1, 2018 | February 28, 2023 | KURIAN, ALLISON W. | reporter.nih.gov |
| Copy Number Alterations in Low Mutation Cancer | NIH | National Cancer Institute | 2021 | $246,525 | December 1, 2018 | March 31, 2022 | DELANEY, JOE R | reporter.nih.gov |
| NCI PATTERNS OF CARE STUDY-DIAGNOSIS YEAR 2021 (PROSTATE CANCER AND OVARIAN CANCER) | NIH | National Cancer Institute | 2024 | $244,943 | May 1, 2024 | April 30, 2025 | SHRESTHA, ANSHU | reporter.nih.gov |
| Pharmacological Potential of Combined Translation and Autophagy Inhibition in High Grade Serous Ovarian Cancer | NIH | National Institute of General Medical Sciences | 2024 to 2025 | $241,944 | August 1, 2024 | July 31, 2026 | KAWEESA, ELIZABETH | reporter.nih.gov |
| Causal determinants of drug resistance and metastasis in cancer with multimodal single cell data | NIH | National Cancer Institute | 2023 to 2024 | $231,852 | February 1, 2023 | January 31, 2026 | SALEHI, SOHRAB | reporter.nih.gov |
| Overcoming treatment-resistant gynecological cancers by combination of DNA damage response inhibitors | NIH | National Cancer Institute | 2024 to 2025 | $224,104 | September 12, 2024 | August 31, 2029 | XU, HAINENG | reporter.nih.gov |
| Integrative Analysis of the Aging Peritoneum in Metastatic Receptivity | NIH | National Institute on Aging | 2023 to 2025 | $223,458 | September 1, 2020 | December 31, 2025 | HARPER, ELIZABETH | reporter.nih.gov |
| Cancer therapy by targeting innate immune cells in vivo using novel virus-like particles | NIH | National Cancer Institute | 2025 | $222,998 | March 10, 2025 | February 28, 2027 | KAUFMAN, DAN S. | reporter.nih.gov |
| Chromatin basis of cellular senescence and its implication in epithelial ovarian cancer | NIH | National Cancer Institute | 2021 | $221,318 | June 1, 2012 | January 31, 2023 | ZHANG, RUGANG | reporter.nih.gov |
| Identifying novel targets for cancer using high throughput deformability screening | NIH | National Cancer Institute | 2025 | $220,894 | February 1, 2025 | January 31, 2027 | ROWAT, AMY C | reporter.nih.gov |
| Characterization of EPHA3 intragenic rearrangements in high-grade serous carcinoma progression and recurrence | NIH | National Cancer Institute | 2021 | $219,491 | February 1, 2020 | January 31, 2023 | WANG, XIAOSONG | reporter.nih.gov |
| Evaluating Deliberative Democracy Approaches with Citizens of African Ancestry Regarding Population Screening for Hereditary Cancer Syndromes | NIH | National Cancer Institute | 2021 | $216,667 | December 3, 2019 | November 30, 2022 | MC BRIDE, COLLEEN M | reporter.nih.gov |
| Targeting FGFR4 to overcome chemoresistance in ovarian cancer | NIH | National Cancer Institute | 2024 | $215,284 | December 5, 2023 | June 30, 2024 | DONG, JIXIN | reporter.nih.gov |
| Spontaneous humoral responses open opportunities for novel immunotherapies against human cancer | NIH | National Cancer Institute | 2022 to 2023 | $214,665 | December 16, 2021 | December 12, 2022 | BISWAS, SUBIR | reporter.nih.gov |
| The role of tumor endothelium-specific prion-gene PRND in epithelial ovarian cancer | NIH | National Cancer Institute | 2022 to 2023 | $213,284 | September 1, 2022 | February 1, 2024 | AL-HILAL, TASLIM A | reporter.nih.gov |
| Response to PQ12 - Using thiol isomerase inhibitors to diminish cancer induced thrombosis | NIH | National Cancer Institute | 2021 | $213,141 | September 1, 2019 | June 30, 2023 | KENNEDY, DANIEL ROBERT | reporter.nih.gov |
| Characterize the metabolic landscape of ARID1A-mutated ovarian cancer | NIH | National Cancer Institute | 2025 | $212,013 | December 1, 2024 | November 30, 2026 | BAZZARO, MARTINA | reporter.nih.gov |
| Investigating PolQ-mediated alternative NHEJ in breast cancer | NIH | National Cancer Institute | 2021 | $210,031 | February 1, 2019 | March 3, 2021 | SFEIR, AGNEL | reporter.nih.gov |
| Regulation of primary metastasis in high grade serous ovarian cancer | NIH | National Cancer Institute | 2021 to 2024 | $209,456 | May 16, 2021 | May 15, 2025 | BERGSTEN, TOVA | reporter.nih.gov |
| Development of a Surgical Drug Delivery System for Enhancement of CAR T Cell Activity | NIH | National Cancer Institute | 2021 to 2024 | $209,456 | September 9, 2021 | September 8, 2025 | BRESSLER, ERIC | reporter.nih.gov |
| Using natural language processing to determine predictors of healthy diet and physical activity behavior change in ovarian cancer survivors | NIH | National Cancer Institute | 2021 | $209,312 | January 1, 2021 | August 15, 2021 | CRANE, TRACY E | reporter.nih.gov |
| Machine Learning-enabled Classification of Extracellular Vesicles Using Nanoplasmonic Microfluidics | NIH | National Institute of Biomedical Imaging and Bioengineering | 2023 to 2024 | $199,919 | December 1, 2022 | September 11, 2024 | HISEY, COLIN LEE | reporter.nih.gov |
| Single cell quantification of genomic instability in cancer as a determinant of therapeutic response | NIH | National Cancer Institute | 2021 to 2022 | $199,596 | March 3, 2021 | February 29, 2024 | WILLIAMS, MARC | reporter.nih.gov |
| Therapeutic potential of FANCM for BRCA1-linked cancer | NIH | National Cancer Institute | 2022 to 2023 | $199,094 | April 1, 2022 | March 31, 2024 | PANDAY, ARVIND | reporter.nih.gov |
| Brca1-Mediated Suppression Of Retrotransposon Activity - Resubmission - 1 | NIH | National Cancer Institute | 2021 | $198,103 | March 7, 2020 | February 28, 2023 | BOEKE, JEF D | reporter.nih.gov |
| Establishing efficient technologies for ovarian cancer organoid derivation from fresh tumor resections | NIH | National Cancer Institute | 2021 | $195,750 | August 1, 2019 | July 31, 2022 | ANDRES-MARTIN, LAURA | reporter.nih.gov |
| NCI PATTERNS OF CARE STUDY FY24 - DIAGNOSIS YEAR 2021 (PROSTATE CANCER AND OVARIAN CANCER) | NIH | National Cancer Institute | 2024 | $193,220 | May 1, 2024 | April 30, 2025 | DURBIN, ERIC | reporter.nih.gov |
| Roles of Hippo signaling and gap junctional communication in follicle development | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2023 | $190,967 | September 1, 2021 | June 3, 2024 | CLARK, KENDRA L | reporter.nih.gov |
| Metabolic basis of ARID1A-mutated ovarian cancer | NIH | National Cancer Institute | 2022 | $184,954 | August 1, 2022 | January 31, 2023 | ZHANG, RUGANG | reporter.nih.gov |
| A Population Based Study of Ketorolac and Ovarian Cancer Survival | NIH | National Cancer Institute | 2021 | $184,469 | February 14, 2020 | June 30, 2021 | COOK, LINDA S | reporter.nih.gov |
| Using natural language processing to determine predictors of healthy diet and physical activity behavior change in ovarian cancer survivors | NIH | National Cancer Institute | 2022 | $181,863 | February 1, 2022 | December 31, 2023 | CRANE, TRACY E | reporter.nih.gov |
| Improving Uptake of Genetic Cancer Risk Assessment in African American Women | NIH | National Cancer Institute | 2021 | $181,487 | December 12, 2019 | May 31, 2023 | SHEPPARD, VANESSA B | reporter.nih.gov |
| Using biomarkers to elucidate the breastfeeding and ovarian cancer risk association | NIH | National Cancer Institute | 2022 to 2023 | $179,000 | March 7, 2022 | December 31, 2024 | SASAMOTO, NAOKO | reporter.nih.gov |
| Repurposing Bruton's tyrosine kinase (BTK) inhibitors to reverse immunosuppression in high-grade serous ovarian cancer (HGSC) | NIH | National Cancer Institute | 2022 to 2023 | $178,000 | July 7, 2022 | June 30, 2024 | GLIMCHER, LAURIE HOLLIS | reporter.nih.gov |
| Type II diabetes, related biomarkers and medications, and ovarian cancer risk | NIH | National Cancer Institute | 2022 to 2023 | $175,999 | February 1, 2022 | January 31, 2025 | HARRIS, HOLLY RUTH | reporter.nih.gov |
| Rational design of drug combinations to target chemotherapy resistance in high-grade serous ovarian cancer via metabolomic profiling of patient-derived organoids | NIH | National Cancer Institute | 2021 to 2022 | $169,500 | July 1, 2021 | June 30, 2024 | KRUMSIEK, JAN | reporter.nih.gov |
| Targeting BRCA1/2-deficient cancers with folate and vitamin C | NIH | National Cancer Institute | 2024 to 2025 | $169,500 | April 1, 2024 | March 31, 2026 | BLENIS, JOHN | reporter.nih.gov |
| Role of miR-195 in Chemo-Resistant Ovarian Cancer | NIH | National Cancer Institute | 2023 | $169,469 | May 1, 2023 | August 14, 2023 | DWIVEDI, SHAILENDRA KUMAR DHAR | reporter.nih.gov |
| Developing macrophage reprogramming mRNA nanocarriers for initial clinical testing | NIH | National Cancer Institute | 2021 | $169,133 | August 1, 2021 | March 31, 2022 | STEPHAN, MATTHIAS | reporter.nih.gov |
| Dissecting clonal determinants of platinum/PARP inhibitor cross-resistance in ovarian cancer | NIH | National Cancer Institute | 2025 | $164,000 | September 1, 2025 | August 31, 2027 | CITRON, FRANCESCA | reporter.nih.gov |
| Impact of diagnostic peritoneal lavage on omentum metastasis | NIH | National Cancer Institute | 2021 to 2022 | $162,000 | July 8, 2021 | December 31, 2023 | NAORA, HONAMI | reporter.nih.gov |
| Mechanisms Underlying the Omental Support of Ovarian Cancer Peritoneal Metastasis | NIH | National Cancer Institute | 2023 to 2025 | $161,206 | June 1, 2023 | August 31, 2027 | MINTZ, RACHEL | reporter.nih.gov |
| Role of Age-Related Changes in the Tumor Microenvironment on Ovarian Cancer Progression | NIH | National Institute on Aging | 2021 to 2022 | $161,000 | August 1, 2021 | April 30, 2024 | HUANG, ZHIQING | reporter.nih.gov |
| Inferring the structure and evolution of tandem duplication towers | NIH | National Cancer Institute | 2022 to 2024 | $158,420 | July 1, 2022 | June 30, 2026 | CHOO, ZI-NING | reporter.nih.gov |
| Examine the function of APOBEC3B in epithelial ovarian cancer stem cells | NIH | National Cancer Institute | 2022 to 2023 | $158,000 | March 1, 2022 | February 29, 2024 | JIANG, QINGFEI | reporter.nih.gov |
| Elucidating pathways underlying the association of contraception use with ovarian cancers through metabolic profiling | NIH | National Cancer Institute | 2025 | $155,605 | September 12, 2025 | August 31, 2026 | MONGIOVI, JENNIFER | reporter.nih.gov |
| Targeting histone methyltransferases EHMT1 and EHMT2 to sensitize PARP inhibitor-resistant ovarian cancer | NIH | National Cancer Institute | 2021 to 2022 | $155,500 | December 3, 2020 | May 31, 2023 | WATSON, ZACHARY LEVI | reporter.nih.gov |
| Infertility and Risk of Breast, Gynecologic, and Colorectal Cancer | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2022 | $153,500 | April 1, 2021 | March 31, 2024 | FARLAND, LESLIE V | reporter.nih.gov |
| Illuminating the functions and translational potential of CDC42BP/MRCK kinases in ovarian cancer | NIH | National Center for Advancing Translational Sciences | 2021 | $151,500 | April 15, 2021 | October 14, 2022 | WANDINGER-NESS, ANGELA | reporter.nih.gov |
| Identification of essential biomarkers in the polyploid cancer cell lifecycle | NIH | National Cancer Institute | 2024 | $151,000 | August 5, 2024 | July 31, 2026 | VOELKEL-JOHNSON, CHRISTINA | reporter.nih.gov |
| Combination Of Autophagy Selective Therapeutics (COAST) in Serous Ovarian Cancer | NIH | National Cancer Institute | 2022 to 2023 | $150,854 | December 1, 2021 | November 30, 2023 | DELANEY, JOE R | reporter.nih.gov |
| Role of protein kinase ADCK5 in ovarian cancer | NIH | National Cancer Institute | 2023 | $150,271 | September 20, 2023 | August 31, 2025 | PADMANABHAN, ACHUTH | reporter.nih.gov |
| Mechanisms of KIT signaling in the regulation of primordial follicle formation | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2023 | $149,021 | August 9, 2022 | July 31, 2025 | PEPLING, MELISSA E | reporter.nih.gov |
| Metabolic targeting of cancer cells via the methylglyoxal detoxification systems | NIH | National Institute of General Medical Sciences | 2021 | $145,000 | February 5, 2019 | December 31, 2022 | TAMAE, DANIEL | reporter.nih.gov |
| T-cell engaging bispecific antibodies designed for proteolytic activation in the tumor microenvironment | NIH | National Cancer Institute | 2021 | $144,870 | July 20, 2021 | April 1, 2022 | RADER, CHRISTOPH | reporter.nih.gov |
| Identifying Combination Therapies in Ovarian Tumors using High Throughput Dynamic BH3 Profiling | NIH | National Cancer Institute | 2022 to 2023 | $143,574 | December 1, 2020 | March 31, 2024 | MCQUEENEY, KELLEY | reporter.nih.gov |
| Evaluating the mechanism by which the DYNLL1-MRE11 complex regulates DNA end resection and genome stability. | NIH | National Institute of General Medical Sciences | 2023 to 2024 | $143,364 | February 1, 2023 | January 31, 2025 | SWIFT, MICHELLE | reporter.nih.gov |
| Defining the role of persistent DNA bridges in tumor-intrinsic immune activation in hereditary breast and ovarian cancer | NIH | National Cancer Institute | 2023 to 2025 | $143,098 | September 1, 2023 | August 31, 2026 | KOCAK, ECE | reporter.nih.gov |
| Structure-Function Investigation of Chemokine-GPCR Signaling in Tumor Progression and Metastasis | NIH | National Cancer Institute | 2021 to 2023 | $141,911 | January 1, 2019 | June 30, 2023 | DISHMAN, ACACIA F | reporter.nih.gov |
| Immunosuppressive Programs Driven by IRE1 signaling in ovarian cancer | NIH | National Cancer Institute | 2021 to 2023 | $140,482 | September 1, 2021 | August 31, 2024 | EMMANUELLI, ALEXANDER | reporter.nih.gov |
| Biochemical and Mechanistic Insights into the Roles of Rad51 Paralogs in Homologous Recombination Repair | NIH | National Cancer Institute | 2021 to 2023 | $140,482 | July 1, 2021 | June 30, 2024 | THRASHER, JACOB GARRETT | reporter.nih.gov |
| Dissecting the role of GPR34 in cDC1 migration and function | NIH | National Cancer Institute | 2023 to 2025 | $135,663 | September 1, 2023 | August 31, 2027 | TAM, HANSON PETER | reporter.nih.gov |
| Targeting Rad18-dependent replication stress pathways to modulate chemoresponse in BRCA1-deficient cancers | NIH | National Cancer Institute | 2021 to 2023 | $134,482 | July 2, 2020 | June 1, 2024 | CYBULLA, EMILY | reporter.nih.gov |
| Exposing the role of MYC in small cell carcinoma of the ovary hypercalcemic type | NIH | National Cancer Institute | 2023 to 2024 | $131,300 | July 5, 2023 | June 30, 2025 | WEISSMILLER, APRIL M. | reporter.nih.gov |
| Host defense mechanisms of resident peritoneal macrophages | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $126,401 | August 1, 2021 | August 31, 2021 | ZHANG, NAN | reporter.nih.gov |
| Ovarian Inflammaging as a Mechanism for Ovarian Cancer | NIH | National Cancer Institute | 2021 to 2023 | $124,419 | July 1, 2021 | May 31, 2024 | DIPALI, SHWETA S. | reporter.nih.gov |
| Targeting HSP70 in CARM1-expressing epithelial ovarian cancer | NIH | National Cancer Institute | 2021 | $119,031 | July 1, 2020 | March 31, 2022 | KARAKASHEV, SERGEY | reporter.nih.gov |
| Photodynamic Alteration of Cell Membrane Lipids to Enhance Chemotherapy Efficacy in Metastatic Ovarian Cancer | NIH | National Cancer Institute | 2025 | $117,018 | August 1, 2025 | July 31, 2027 | OVERCHUK, MARTA | reporter.nih.gov |
| Ovarian cancer risk stratification using circulating miRNAs to assess BRCAness | NIH | National Cancer Institute | 2023 | $116,323 | September 12, 2023 | October 31, 2024 | ELIAS, KEVIN | reporter.nih.gov |
| Inflammation and gynecologic cancer: the role of prostaglandins in ovarian cancer | NIH | National Cancer Institute | 2021 | $114,180 | July 18, 2018 | June 30, 2022 | BARNARD, MOLLIE ELYSE | reporter.nih.gov |
| Genome-wide approaches to non-invasive screening and characterization of ovarian cancers | NIH | National Cancer Institute | 2024 to 2025 | $108,512 | September 1, 2024 | October 31, 2027 | ANNAPRAGADA, AKSHAYA VIJAYA | reporter.nih.gov |
| Development of Tunable Microenvironment-Responsive CAR T Cells Using Synthetic Gene Circuits to Enhance Potency and Safety | NIH | National Cancer Institute | 2024 to 2025 | $108,512 | September 1, 2024 | August 31, 2026 | SCHREIBER, YANNICK RENE | reporter.nih.gov |
| NCI PATTERNS OF CARE STUDY - DIAGNOSIS YEAR 2021 (PROSTATE CANCER AND OVARIAN CANCER) | NIH | National Cancer Institute | 2024 | $104,718 | May 1, 2024 | April 30, 2025 | SCHWARTZ, STEPHEN M | reporter.nih.gov |
| The Impact of Maternal Obesity on the Reprogramming of the Metastatic Microenvironment | NIH | National Cancer Institute | 2021 | $103,375 | August 1, 2017 | July 31, 2023 | HILLIARD, TYVETTE | reporter.nih.gov |
| Manipulation of three-dimensional chromatin structure to regulate oncogenes in breast and ovarian cancer. | NIH | National Cancer Institute | 2021 | $101,374 | July 6, 2018 | December 31, 2021 | MORGAN, STEFANIE L | reporter.nih.gov |
| NCI PATTERNS OF CARE STUDY FY24 - DIAGNOSIS YEAR 2021 (PROSTATE CANCER AND OVARIAN CANCER) | NIH | National Cancer Institute | 2024 | $99,442 | May 1, 2024 | April 30, 2025 | MANISCALCO, LAUREN | reporter.nih.gov |
| Defining tumor and blood-based immunogenomic signatures predicting response to immunotherapy in ovarian cancer | NIH | National Cancer Institute | 2025 | $99,171 | December 1, 2024 | November 30, 2028 | MONSON, KELSEY R | reporter.nih.gov |
| Mapping p53 dynamics to cell-fate outcomes in reprogramming and oncogenesis | NIH | National Cancer Institute | 2023 to 2024 | $98,168 | August 11, 2023 | July 31, 2025 | BEITZ, ADAM MATTHEW | reporter.nih.gov |
| Combining repetitive element-specific T cells with epigenetic therapy to treat ovarian cancer | NIH | National Cancer Institute | 2022 to 2024 | $97,254 | May 1, 2022 | August 31, 2024 | GRUNDY, ERIN ELIZABETH | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| University of TX MD Anderson Can CTR | Houston, TX | 24 | $30 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 16 | $22.3 million | 0 | $0 |
| Marshall University Research Corporation | Huntington, WV | 1 | $20.3 million | 0 | $0 |
| Harvard University D/b/a Harvard School of Public Health | Boston, MA | 2 | $15.4 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 11 | $15.2 million | 0 | $0 |
| Mayo Clinic Rochester | Rochester, MN | 12 | $14.5 million | 0 | $0 |
| University of Kansas Medical Center | Kansas City, KS | 2 | $13.6 million | 0 | $0 |
| Sloan-Kettering Inst Can Research | New York, NY | 10 | $13.4 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 12 | $13.1 million | 0 | $0 |
| University of Washington | Seattle, WA | 7 | $12.9 million | 0 | $0 |
| Fred Hutchinson Cancer Center | Seattle, WA | 6 | $10.4 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 8 | $10 million | 0 | $0 |
| Yale University | New Haven, CT | 6 | $9.9 million | 0 | $0 |
| Washington University | Saint Louis, MO | 12 | $9.6 million | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 8 | $9 million | 0 | $0 |
| Stanford University | Stanford, CA | 7 | $8.8 million | 0 | $0 |
| Dana-Farber Cancer Inst | Boston, MA | 12 | $8.8 million | 0 | $0 |
| Emory University | Atlanta, GA | 7 | $8.6 million | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 8 | $7.7 million | 0 | $0 |
| University of Wisconsin-Madison | Madison, WI | 7 | $7 million | 0 | $0 |
| University of Texas HLTH Science Center | San Antonio, TX | 7 | $6.9 million | 0 | $0 |
| University of Chicago | Chicago, IL | 6 | $6.9 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 5 | $6.8 million | 0 | $0 |
| University of Utah | Salt Lake City, UT | 5 | $6.7 million | 0 | $0 |
| Ohio State University | Columbus, OH | 6 | $6.6 million | 0 | $0 |
| H. Lee Moffitt Cancer CTR & Res Inst | Tampa, FL | 9 | $6.3 million | 0 | $0 |
| Trustees of Boston University | Boston, MA | 6 | $6.2 million | 0 | $0 |
| Magee-Women's Res Inst and Foundation | Pittsburgh, PA | 6 | $6.2 million | 0 | $0 |
| Northwestern University at Chicago | Chicago, IL | 8 | $6.1 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 6 | $6.1 million | 0 | $0 |
| Indiana University Indianapolis | Indianapolis, IN | 5 | $5.9 million | 0 | $0 |
| Research Inst of Fox Chase Can CTR | Philadelphia, PA | 4 | $5.8 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 10 | $5.6 million | 0 | $0 |
| New York University School of Medicine | New York, NY | 5 | $5.5 million | 0 | $0 |
| George Washington University | Washington, DC | 7 | $5.5 million | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 7 | $5.4 million | 0 | $0 |
| Cedars-Sinai Medical Center | Los Angeles, CA | 6 | $5.1 million | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 3 | $5 million | 0 | $0 |
| University of Illinois at Chicago | Chicago, IL | 5 | $5 million | 0 | $0 |
| University of New Mexico Health Scis CTR | Albuquerque, NM | 9 | $4.9 million | 0 | $0 |
| University of Maryland, College Park | College Park, MD | 2 | $4.8 million | 0 | $0 |
| Roswell Park Cancer Institute Corp | Buffalo, NY | 3 | $4.8 million | 0 | $0 |
| Oregon Health & Science University | Portland, OR | 4 | $4.8 million | 0 | $0 |
| University of California-Irvine | Irvine, CA | 2 | $4.7 million | 0 | $0 |
| Beth Israel Deaconess Medical Center | Boston, MA | 3 | $4.6 million | 0 | $0 |
| Rutgers Biomedical and Health Sciences | Newark, NJ | 5 | $4.5 million | 0 | $0 |
| Beckman Research Institute/city of Hope | Duarte, CA | 3 | $4.5 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 6 | $4.4 million | 0 | $0 |
| Northeastern University | Boston, MA | 2 | $4 million | 0 | $0 |
| Duke University | Durham, NC | 6 | $4 million | 0 | $0 |
| Univ of North Carolina Chapel Hill | Chapel Hill, NC | 3 | $3.8 million | 0 | $0 |
| Medical University of South Carolina | Charleston, SC | 6 | $3.7 million | 0 | $0 |
| Baylor College of Medicine | Houston, TX | 4 | $3.6 million | 0 | $0 |
| University of Arizona | Tucson, AZ | 3 | $3.6 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 6 | $3.5 million | 0 | $0 |
| University of Nebraska Medical Center | Omaha, NE | 5 | $3.4 million | 0 | $0 |
| University of Oklahoma HLTH Sciences CTR | Oklahoma City, OK | 4 | $3.4 million | 0 | $0 |
| Massachusetts Institute of Technology | Cambridge, MA | 4 | $3.4 million | 0 | $0 |
| SUNY at Buffalo | Amherst, NY | 2 | $3.4 million | 0 | $0 |
| University of California at Davis | Davis, CA | 3 | $3.4 million | 0 | $0 |
| University of Maryland Baltimore | Baltimore, MD | 4 | $3.3 million | 0 | $0 |
| Medical College of Wisconsin | Milwaukee, WI | 4 | $3.2 million | 0 | $0 |
| University of Florida | Gainesville, FL | 3 | $3.2 million | 0 | $0 |
| University of Connecticut SCH of Med/dnt | Farmington, CT | 2 | $3.1 million | 0 | $0 |
| University of Iowa | Iowa City, IA | 3 | $3 million | 0 | $0 |
| University of California Los Angeles | Los Angeles, CA | 4 | $2.9 million | 0 | $0 |
| Methodist Hospital Research Institute | Houston, TX | 2 | $2.9 million | 0 | $0 |
| Brandeis University | Waltham, MA | 1 | $2.5 million | 0 | $0 |
| University of Alabama at Birmingham | Birmingham, AL | 4 | $2.5 million | 0 | $0 |
| Up Therapeutics, Inc. | Frederick, MD | 2 | $2.4 million | 0 | $0 |
| Cornell University | Ithaca, NY | 2 | $2.4 million | 0 | $0 |
| University of Virginia | Charlottesville, VA | 3 | $2.3 million | 0 | $0 |
| Children's Hosp of Philadelphia | Philadelphia, PA | 1 | $2.3 million | 0 | $0 |
| Geisinger Clinic | Danville, PA | 1 | $2.2 million | 0 | $0 |
| CUNY Brooklyn College | New York, NY | 3 | $2.2 million | 0 | $0 |
| Fred Hutchinson Cancer Research Center | Seattle, WA | 7 | $2.2 million | 0 | $0 |
| Rutgers University New Brunswick | New Brunswick, NJ | 4 | $2.2 million | 0 | $0 |
| Oregon State University | Corvallis, OR | 1 | $2.2 million | 0 | $0 |
| Celdara Medical, LLC | Lebanon, NH | 2 | $2.1 million | 0 | $0 |
| Henry Ford Health System | Detroit, MI | 2 | $2.1 million | 0 | $0 |
| Nami Therapeutics Corp. | Storrs, CT | 1 | $2 million | 0 | $0 |
| Cynvec, LLC | New York, NY | 1 | $2 million | 0 | $0 |
| Molecular Targeting Technologies, Inc. | West Chester, PA | 1 | $2 million | 0 | $0 |
| Aprea Therapeutics, Inc. | Boston, MA | 1 | $2 million | 0 | $0 |
| Wistar Institute | Philadelphia, PA | 6 | $2 million | 0 | $0 |
| Kaiser Foundation Research Institute | Oakland, CA | 1 | $2 million | 0 | $0 |
| Mayo Clinic Jacksonville | Jacksonville, FL | 1 | $1.9 million | 0 | $0 |
| University of Miami School of Medicine | Coral Gables, FL | 3 | $1.8 million | 0 | $0 |
| Brown University | Providence, RI | 1 | $1.8 million | 0 | $0 |
| Lurie Children's Hospital of Chicago | Chicago, IL | 1 | $1.8 million | 0 | $0 |
| Georgia Tech Research Corporation | Atlanta, GA | 1 | $1.7 million | 0 | $0 |
| Integral Molecular | Philadelphia, PA | 1 | $1.7 million | 0 | $0 |
| San Diego State University Foundation | San Diego, CA | 1 | $1.6 million | 0 | $0 |
| Case Western Reserve University | Cleveland, OH | 1 | $1.6 million | 0 | $0 |
| Wayne State University | Detroit, MI | 2 | $1.5 million | 0 | $0 |
| University of Connecticut | Storrs, CT | 1 | $1.4 million | 0 | $0 |
| Georgetown University | Washington, DC | 2 | $1.4 million | 0 | $0 |
| Mayo Clinic Arizona | Scottsdale, AZ | 1 | $1.4 million | 0 | $0 |
| Van Andel Research Institute | Grand Rapids, MI | 1 | $1.4 million | 0 | $0 |
| University of South Carolina at Columbia | Columbia, SC | 1 | $1.3 million | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 238 | $123,439,478 | 0 | $0 |
| 2024 | 263 | $115,924,309 | 0 | $0 |
| 2023 | 261 | $112,993,847 | 0 | $0 |
| 2022 | 267 | $117,661,943 | 0 | $0 |
| 2021 | 287 | $116,258,831 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed) | PA-24-194 | NIH | May 7, 2027 | Not listed | Notice number printed on 2 awards here | |
| Change of Recipient Organization (Type 7 Parent Clinical Trial Optional) | PA-24-254 | NIH | July 12, 2027 | Not listed | Notice number printed on 1 award here | |
| NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed) | PAR-27-089 | NIH | 93.395 | November 2, 2026 | Not listed | Same assistance listing 93.395 as 164 awards here |
| Precision Approaches in Radiation Synthetic Combinations (PAIRS, RP1 Clinical Trial Optional) | PAR-26-152 | NIH | 93.395 | November 11, 2026 | Not listed | Same assistance listing 93.395 as 164 awards here |
| NCI Research Specialist Award for Core and Laboratory-based Scientists (R50 Clinical Trial Not Allowed) | PAR-27-088 | NIH | 93.395 | November 20, 2026 | Not listed | Same assistance listing 93.395 as 164 awards here |
| Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required) | PAR-24-214 | NIH | 93.395 | January 7, 2027 | $375,000 | Same assistance listing 93.395 as 164 awards here |
| Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional) | PAR-25-079 | NIH | 93.395 | January 7, 2027 | $500,000 | Same assistance listing 93.395 as 164 awards here |
| National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required) | PAR-25-081 | NIH | 93.395 | January 7, 2027 | $499,999 | Same assistance listing 93.395 as 164 awards here |
| Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required) | RFA-CA-27-005 | NIH | 93.395 | January 11, 2027 | $700,000 | Same assistance listing 93.395 as 164 awards here |
| Single Source: Coordinating Center (CC) for the Small Cell Lung Cancer (SCLC) Consortium (U24 Clinical Trial Not Allowed) | PAR-27-009 | NIH | 93.395 | January 25, 2027 | Not listed | Same assistance listing 93.395 as 164 awards here |
| Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed) | RFA-CA-26-010 | NIH | 93.395 | January 25, 2027 | Not listed | Same assistance listing 93.395 as 164 awards here |
| Radiation Oncology-Biology Integration Network (ROBIN) Centers (U54 Clinical Trial Required) | RFA-CA-27-003 | NIH | 93.395 | January 25, 2027 | Not listed | Same assistance listing 93.395 as 164 awards here |
| NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) | PA-27-100 | NIH | 93.395 | April 5, 2027 | Not listed | Same assistance listing 93.395 as 164 awards here |
| NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional) | PA-27-102 | NIH | 93.395 | April 5, 2027 | Not listed | Same assistance listing 93.395 as 164 awards here |
| Advanced Development and Sustainment of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) | RFA-CA-28-003 | NIH | 93.395 | June 11, 2027 | $600,000 | Same assistance listing 93.395 as 164 awards here |
| Successor-in-Interest (Type 6 Parent Clinical Trial Optional) | PA-24-253 | NIH | 93.395 | July 17, 2027 | Not listed | Same assistance listing 93.395 as 164 awards here |
| NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed) | PA-25-080 | NIH | 93.395 | September 7, 2027 | Not listed | Same assistance listing 93.395 as 164 awards here |
| Bioengineering Partnerships with Industry (U01 Clinical Trial Optional) | PAR-24-325 | NIH | 93.395 | September 7, 2027 | Not listed | Same assistance listing 93.395 as 164 awards here |
| Investigator-Focused Award (Parent R35) | PAR-28-037 | NIH | 93.395 | October 4, 2027 | Not listed | Same assistance listing 93.395 as 164 awards here |
| Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional) | RFA-CA-27-019 | NIH | 93.395 | October 19, 2027 | $300,000 | Same assistance listing 93.395 as 164 awards here |
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.